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Abstract
Type 2 diabetes (T2D) is one of the fastest growing public health concerns in the
United States. There were 30.3 million patients (9.4% of the US populations) suffer-
ing from diabetes in 2015. Diabetes, which is the seventh leading cause of death in
the United States, is known to be a non-reversible (incurable) chronic disease, leading
to severe complications, including chronic kidney disease, amputation, blindness, and
various cardiac and vascular diseases. Early identification of patients at high risk is
regarded as the most effective clinical tool to prevent or delay the development of di-
abetes, allowing patients to change their life style or to receive medication earlier. In
turn, these interventions can help decrease the risk of diabetes by 30-60%.
Many studies have been conducted aiming at the early identification of patients at
high risk in the clinical settings. These studies typically only consider the patient’s cur-
rent state at the time of the assessment and do not fully utilize all available information
such as patient’s medical history. Past history is important. It has been shown that
laboratory results and vital signs can differ between diabetic and non-diabetic patients
as many as 15-20 years before the onset of diabetes. We have also shown in our study
that the order in which patients develop diabetes-related comorbidities is predictive of
their diabetes risk even after adjusting for the severity of the comorbidities.
In this thesis, we develop multiple novel methods to discover T2D trajectories from
Electronic Health Records (EHR). We define trajectory as an order of in which diseases
developed. We aim to discover typical and atypical trajectories where typical trajectories
represent predominant patterns of progressions and atypical trajectories refer to the
rest of the trajectories. Revealing trajectories can allow us to divide patients into
subpopulations that can uncover the underlying etiology of diabetes. More importantly,
by assessing the risk correctly and by a better understanding of the heterogeneity of
diabetes, we can provide better care.
Since data collected from EHR poses several challenges to directly identify trajec-
tories from EHR data, we devise four specific studies to address the challenges: First,
we propose a new knowledge-driven representation for clinical data mining, second, we
iv
demonstrate a method for estimating the onset time of slow-onset diseases from inter-
mittently observable laboratory results in the specific context of T2D, third, we present
a method to infer trajectories, the sequence of comorbidities potentially leading up to
a particular disease of interest, and finally, we propose a novel method to discover mul-
tiple trajectories from EHR data. The patterns we discovered from above four studies
address a clinical issue, are clinically verifiable and are amenable to deployment in prac-
tice to improve the quality of individual patient care towards promoting public health
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Type 2 diabetes (T2D) is one of the fastest growing public health concerns in the United
States[1]. There were 30.3 million patients (9.4% of the US populations) suffering from
diabetes in 2015[2]. Diabetes, which is the seventh leading cause of death in the United
States, is known to be a non-reversible (incurable) chronic disease[3, 4], leading to severe
complications[5, 1], including chronic kidney disease, amputation, blindness, and various
cardiac and vascular diseases. Early identification of patients at high risk is regarded as
the most effective clinical tool to prevent or delay the development of diabetes through
life style change or early pharmaceutical intervention. In turn, these interventions can
help decrease the risk of diabetes by 30-60%[6, 7].
Many studies[8, 9] have been conducted aiming at the early identification of patients
at high risk in the clinical settings. These studies typically only consider the patient’s
current state at the time of the assessment and do not fully utilize all available informa-
tion such as patient’s medical history. Past history is important. It has been shown that
laboratory results and vital signs can differ between diabetic and non-diabetic patients
as many as 15-20 years before the onset of diabetes[10]. We have also shown in our study
that the order in which patients develop diabetes-related comorbidities is predictive of
their diabetes risk even after adjusting for the severity of the comorbidities[11].
Understanding patients’ disease progression over time has the potential to enable
new levels of personalized intervention strategies, but it requires rich clinical data and
novel machine learning methods.
The recent adaptation of electronic health records (EHR)[12, 13] allows us to access
1
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large volumes of rich, longitudinal clinical data inexpensively. These data consist of
information about patients’ health, including diagnoses, medications, vital signs, and
laboratory results, thus combining them into a model would result in a detailed model
that can improve diagnosis, prognosis, and if interpretable, even our understanding of
diseases and patient population[14, 15, 16, 11, 17]. However, the EHR is not designed
and collected for research purposes, and, thus, the use of data, as it exists in the
EHR, poses several challenges including unreliable diagnosis code[18], missing not at
random[19, 20, 21], and inaccurate time stamps[11, 22]. Before we can develop methods
for extracting disease progression patterns from EHR data, we have to address these
challenges. In this thesis, we developed a methods for estimating and validating the
onset time of diseases, and have developed novel data representations, particularly for
clinical data mining purposes.
The focus of this thesis is on discovering T2D trajectories from EHR data. We define
a trajectory as the natural order in which diseases develop. We aim to discover typical
and atypical trajectories where typical trajectories represent predominant patterns of
progressions and atypical trajectories refer to the rest of the trajectories. Knowledge
about trajectories can help us divide patients into subpopulations, reveal the underlying
etiology of diabetes, and more importantly, it can help us assess the risk of diabetes
and its complication more correctly. In aggregate, this knowledge can lead to a better
understanding of the heterogeneity of diabetes, and subsequently, to better and more
individualized care.
Since the transferability of models and the reproducibility of findings[23, 24, 25] are
the key concern of the machine learning-oriented studies, we evaluate and validate the
proposed methods on cohorts from two large healthcare systems in the Upper Midwest
United States.
Learning trajectories can be approached from two different perspectives. First, tra-
jectories can be viewed as simply a sequences of events, and existing sequence learning
methods[26] can be applied. Second, the diseases along a trajectory can also be viewed
as causally linked events, where the development of a diseases causes progression to the
next disease. This second perspective allows us to use causal structure discovery[27, 28]
methods for trajectory mining. However, despite the recent success of these models in
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medical researches[29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39], these methods are not de-
signed to solve the problem of extracting sequences themselves from partially observable
EHR data and are therefore unable to extract full sequences and may extract sequences
with incorrect ordering caused by inaccurate time stamps. In this thesis, we develop a
novel methodology that successfully addresses these issues.
1.1 Dissertation organization
The remainder of this thesis is organized into six chapters: In Chapter 2 we review
recent literature regarding the key challenges in using data from EHRs for clinical re-
search purpose, data representations and trajectories; in Chapter 3 we propose a new
knowledge-driven representation for clinical data mining and study which characteris-
tics make representations most suitable for particular clinical analytics tasks including
trajectory mining; in Chapter 4 we demonstrate a method for estimating the onset time
of slow-onset diseases from intermittently observable laboratory results in the specific
context of T2D; in Chapter 5 we propose a new method for inferring T2D trajectories,
defined as a sequence of comorbidities (i.e., hyperlipidemia, hypertension, and impaired
fasting glucose), using EHR; in Chapter 6 we propose a new computational method for
learning disease trajectories from EHR data that can help revealing some of the underly-
ing mechanisms and their associated risk of developing diabetes; and finally in Chapter
8 we conclude the thesis by providing a summary of our work with contributions to
Science section discusses the benefits of this particular research.
Chapter 2
Background
2.1 Electronic Health Records
The widespread adoption of Electronic Health Records (EHR)[12, 13] in recent years
offers us the opportunity to unlock the potential of personalized medicine. The EHR
allows us to inexpensively obtain rich clinical data consisting of laboratory results,
diagnoses, medications, vital signs and social descriptors for large patient populations.
These data elements all contribute information about patients’ health, thus combining
them into a model would result in a detailed model[14, 15, 16, 11, 17] that can take into
account individual differences, and consequently, can improve diagnosis and prognosis
compared to population-based models. However, since the EHR is not designed for the
purpose of research, there are several challenges in discovering trajectories.
2.1.1 Challenges of using EHR data for the Discovery of Type 2 Dia-
betes Trajectories
The secondary use of EHR data poses numerous challenges. So many, in fact, that
reviewing them comprehensively is outside the scope of this work. In this section, we
focus on the challenges that are anticipated in our work of discovering trajectories.
First, missing data is prevalent in EHR, but most of them are informative missing
data[19, 20, 21] (also called missing not at random). Informative missing data refers to
the missingness whereby the probability of a missing value is dependent on the value
4
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that is missing. As an example, a majority of missing laboratory test results imply the
absence of clinical signs or symptoms of the target disease since laboratory tests won’t
be ordered without clinical justification.
Second, some essential information is stored in an unstructured format (if at all)
hidden within narrative clinical notes[40, 41, 42]. For example, lifestyle interventions
are the first line of defense in both the prevention and the management of diabetes, yet
related information is unavailable in structured format in the EHR.
Third, we cannot determine the onset time of disease precisely[11, 42]. The onset
time of disease is the earliest time when the patient meets the diagnostic criteria for the
disease. Many analytical methods rely on the onset time of disease, but we can only
access the recorded time of disease, the time when the disease is discovered and recorded
into EHR. The failure of extracting accurate onset times and the use of the recorded
times as an alternative is of key importance especially for trajectory mining because
there can be a large gap between the onset time and the recorded time of disease.
Fourth, we can directly observe only part of the disease progressions since patients’
medical history in EHR can be insufficient to cover the entire disease progressions and
can be fragmented across multiple providers[43, 44]. As an example, the development of
slow-onset conditions, such as T2D and its comorbidities can take decades. Even with
13 years of follow-up, we can only observe partial trajectories, that is, the development
of only a few new conditions. Therefore, if we tried to observe full trajectories under this
constraint, we would focus on patients with the fastest progression, possibly biasing the
results. We will discuss how these challenges affect trajectory mining later in Section
2.4.
2.2 Type 2 Diabetes
2.2.1 Pathophysiology of diabetes
Insulin secretion and the regulation of glucose and lipid metabolism are the key concepts
for understanding the pathogenesis of diabetes[45, 46]. Human brain, liver and skeletal
muscle are the organs that can store glucose[45]. The brain is known to be insulin-
independent glucose uptake organ i.e. the amount of uptake is not governed by the
amount of inulin in the blood, while the liver and skeletal muscle are known to be
6
insulin-dependent glucose uptake organ. When the plasma glucose is concentrated on
the blood, insulin is released from the beta cell of the pancreases to accelerate uptake
of glucose and fatty acids into insulin sensitive tissue. This uptake will give negative
feedback to the beta cell and will decrease secretion of the insulin. This feedback loop
leads to the homeostasis of glucose concentration on the blood.
Diabetes[47, 48, 49] is characterized by loss of homeostasis of glycemic control by
reduced insulin secretion or insulin action or both. Diabetes is generally categorized
into two categories; Type 1 and 2. In Type 1 Diabetes, the malfunction of autoimmune
system results in a lack of beta cells of the islets of Langerhans causing a loss of ability to
secret insulin. In contrast, in Type 2 Diabetes, insulin is present in sufficient amounts,
but insulin sensitive tissues such as skeletal muscle cells, adipose tissues and liver fail
to react to insulin. Although when we refer to ‘diabetes’, we commonly refer to these
two types, in fact, diabetes has various subtypes including maturity-onset diabetes in
the young (MODY)[50] and latent autoimmune diabetes of adults (LADA)[51].
2.2.2 Prevalence and significance of Type 2 Diabetes
In the United States, Type 2 Diabetes affects 29.1 million people or 9.3% of the US pop-
ulation with an additional 8.1 million people undiagnosed in 2014[52] and it is growing
compared with 2011 (25.8 million)[53]. The rate of growth is higher than expected. As
of 2001, the prevalence of diabetes was expected to grow to 7.2% by 2050[54], but has
already reached 9.2% in 2014. Newer studies expect the prevalence of diabetes to be
21% in 2050[55].
Diabetes can lead to various complications, including blindness, chronic kidney dis-
ease, kidney failure and various cardiac and vascular diseases[5, 1] and it is the seventh
leading cause of death in the United States[1]. The total cost for US diabetic patients
in 2012[56] is estimated $245 billion. Average estimated medical cost for each patient




EHR systems[12] store information about entire populations and offer long follow-
up times. Since EHR is not designed for supporting clinical analytics, data directly
collected from EHR is not ready to be used in trajectory mining methods. A data
representation[57, 58] is a transformation of data into a format amenable to the par-
ticular analytic technique. In this section, we will briefly review methods for data
representation, and discuss their applicability to trajectory mining.
Representations can be categorized as outcome-specific or outcome-independent.
Outcome-specific data representations are specific to a particular study end point (out-
come) and are not applicable to different end points, while outcome-independent rep-
resentations do not consider an outcome. For example, a diabetes risk score is an
outcome-specific data representation which would not be used to estimate the risk of
other diseases, cardiovascular disease as an example; but a comorbidity index is an
outcome-independent data representation and it can be used for numerous outcomes
(readmission, re-hospitalization, short-term mortality, etc).
2.3.1 Outcome-specific Representation—Severity Score
Disease severity score[59] (also disease severity scale[60] or disease severity index[61])
quantifies disease burden with respect to some outcome of interest. For example, the
Framingham diabetes score[46] associates disease burden, defined by a handful of risk
factors, with the risk of developing diabetes (an outcome). Traditionally, regression
analysis is extensively used: the Framingham score is derived from a logistic regression
model with 8-year diabetes status as the dependent variable and various diabetes risk
factors as the independent variables. Severity score is a dimensionality-reducing repre-
sentation, as it summarizes numerous original risk factors into a single number, which is
proportional to the burden conferred by those risk factors on some outcome. Although
the construction of severity scores through regression models requires an outcome, they
can still be outcome-independent by using mortality as a generic outcome[62].
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2.3.2 Outcome-independent Representations
Outcome-independent representations transform the original data into a new set of fea-
tures, typically with a different dimensionality. Many currently existing representations,
such as principal component analysis (PCA)[63] and nonnegative matrix factorization
(NMF)[64, 65] have the specific aim of reducing the problem dimensionality. PCA is
a statistical procedure that transforms a set of features into a new set of orthogonal
features (called principal components), and NMF factorizes the original matrix into
two matrices having only non-negative values, in a way that each subsequent compo-
nent captures maximal amount of the residual information. Dimensionality reduction
is achieved by using only the first few components.
Deep neural networks (DNNs)[66] are computational models that are inspired by
neural networks in animal brains and have recently achieved considerable success. Much
of this success is attributed to the data representation of these techniques, which is
known as de-noising autoencoders (DAE)[67, 68]. DAEs consist of successive layers
of transformations, where the outcome of each layer is the input to the next. Each
layer is thought to extract higher-level features than the previous. The criterion for
goodness of the transformation is the reconstruction error, which is a measure of how
well an autoencoder can reconstruct the original data from its output. Autoencoders can
perform dimensionality reduction or expansion. Requirements of Data representations
for the Discovery of Type 2 Diabetes Trajectories
2.3.3 Requirements of Data representations for the Discovery of Type
2 Diabetes Trajectories
An ideal data representation for disease trajectory mining would have the following
characteristics. First, data representation needs to show high performance on analytics
based on binary or event data. This is because our goal is to discover trajectories
where a trajectory is a sequence of “events” towards a certain outcome. Second, data
representation needs to show high interpretability. Our long-term goal is to reveal T2D
trajectories that can be practically applied in a clinical setting where its success depends
on interpretability of data representation.
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None of the above data representation meets both requirements. Outcome inde-
pendent representations, such as PCA and NMF, tend to show lower performance and
lower interpretability because the aim of the outcome independent representations is
to minimize reconstruction error in general. These representations show lower perfor-
mance than outcome-dependent representations with the same number of features. On
the other hand, outcome-dependent representations, severity scores in particular, show
high performance and good interpretability because the aim of the representations is
to quantify the severity of target disease. This allows us to have high performance
by minimizing outcome specific information loss and guaranteed interpretability since
scores tell the severity of patient’s condition directly. However, the outcome-dependent
representations are not suitable to trajectory mining. Severity score, as an example
of outcome-dependent representations, is a projection of high-dimensional space onto
a linear subspace in accordance with the risk of an impending adverse event or mor-
tality. Accordingly, different conditions from separate physiological mechanisms can
be projected onto the same point. For this reason, the use of the outcome-dependent
representations shows a limited ability to discover disease trajectory.
2.4 Trajectory mining
In this section, we focus on the methods for learning trajectories from data. The common
methods are sequential pattern mining and causal structure learning. We will review
these methods, and discuss how the unique characteristics of data from EHR can affect
the applicability of these methods for the discovery of disease trajectories.
2.4.1 Sequential pattern mining
The goal of sequential pattern mining[26] is to discover the complete set of subsequences
that appeared frequently in a database of sequences where a sequence is a set of ordered
elements and a subsequence is an ordered subset of the elements in the sequence. As
an example of disease progressions, elements are diseases and subsequences are partial
trajectories. Thus, with sequential pattern mining, we can extract partial trajectories
of disease progression. However, our interest is not to discover partial trajectories but
to infer full trajectories from partial trajectories.
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Since there can be an excessive number of sequential patterns, much effort is di-
rected at reducing the number of patterns. First, some studies proposed methods for
discovering so called closed sequential patterns. A sequential pattern s is closed if there
is no supersequence with the same support as s. The closed sequential patterns can have
the same information as non-closed sequential patterns with fewer patterns. Therefore,
disease trajectories based on closed sequential patterns guarantee to have minimal sub-
sets which can lead to improving interpretability as well. Second, some studies proposed
methods for discovering sequential patterns with user-specified constraints. Minimum
frequency of each pattern for sequential patterns and sliding window approach are the
common approaches to define user-specified constraints. Domain knowledge is also used
for deriving user-specific constraints frequently, such as ‘diabetes is a non-reversible
chronic disease so that patient’s conditions are getting worse over time”. These user-
specified constraints allow us to reduce the search space and to discover only sequential
patterns that are of the interest. For this reason, the user-specified constraints allow
us to discover disease trajectories where each progression pair has particular clinical
meaning.
Sequential pattern mining has been applied to reveal short sequences of events in
clinical settings including readmission[38, 39] and adverse events[32, 35, 36], however, its
application to trajectory mining is limited for the following reasons. First, we can only
access the recorded time of the disease rather than the onset time of the disease. Se-
quential pattern mining relies on accurate timestamps to determine the order of events.
However, some diseases can be discovered through the diagnosis of their complications,
and the order of events can be invalid. Second, patient visits are intermittent so that
we could observe multiple events occurring at the same time from EHR data. In real-
ity, they could have developed at different time points but were merely discovered and
recorded at the same time. This lack of ordering can also lead to the discovery of in-
valid trajectories or to the failure to discover some valid trajectories. Third, we cannot
access patient’s entire medical history in EHR. Even with 13 years follow-up history in
our data, we cannot observe full trajectories. Therefore, we can only extract multiple
partial and truncated trajectories from sequential pattern mining. Finally, sequential
pattern mining does not have the concept of independent trajectories, and can hence
capture multiple overlapping trajectories by chance.
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Sequential pattern mining, as it exists today, requires overcoming the challenges
in using EHR data for trajectory mining. Our method is based on sequential pattern
mining but with appropriate adaptations. Structure learning
2.4.2 Structure learning
Another class of methods, that we could use for trajectory mining, is structure learning[27,
28]. The goal of structure learning is a little different from finding trajectories; it is a
framework for learning the structure of graphs where graphs consist of a finite set of
nodes and a set of directed edges. Most structure learning methods focus on reveal-
ing structure for causal inference. Our interest, however, is not to discover the causal
structure but to discover precedence of associated events.
There are two major approaches to structure learning: constraint-based and score-
based. Constraint-based structure learning is a set of processes that conducts condi-
tionally independent tests to identify a set of edges based on the evaluation of faith-
fulness assumption, and to find the best directed acyclic graph (DAG) that satisfies
the constraints. Score-based structure learning is a set of iterative processes that find
a graph with maximal score. Some studies have shown the effectiveness of structure
learning to solve various clinical tasks including monitoring[69], screening, diagnosis
and prognosis[29, 30, 31, 33, 34, 37]. However, only a few studies so far have attempted
to discover disease trajectories. In principle, we could discover causal chains and treat
them as trajectories, however, this is overly restrictive as we are primarily interested in
precedence: it is highly unlikely that comorbidities in diabetes cause each other; it is
more likely that the comorbidities are clinical manifestations of a common underlying
metabolic degradation. Also, the uncertainty in the timestamps and the observed se-
quence of events makes reconstruction of a causal graph challenging; our methodology, if
successful, could provide the much needed precedence information that these structure
learning methods require.
Our trajectories are not intended to be causal. We are primarily interested in prece-
dence. In a way, our method, which will be explained in the later section, is comple-
mentary to the causal discovery methods: the (hopefully) robust precedence information
extracted by our method makes structure learning possible (or easier).
Chapter 3
A new knowledge-driven
representation for clinical data
mining
3.1 Introduction
The widespread adoption of electronic health records (EHR)[12] enables new kinds of
analytics such as explicitly modeling population heterogeneity or identifying benefit
groups for an intervention[14, 15, 16, 70, 11, 71]. It is well understood that different
analytics tasks and techniques operate optimally on different types of data[57, 58]. For
example, association pattern mining requires binary or categorical data[72] and most
regression models assume that the predictor variables have an additive effect[73]. Data,
as it exists in the EHR, is not ideal for many analytics tasks.
A data representation is a transformation of data into a format amenable to a
particular analytic technique. Data transformations are not new, e.g., log or rank
transformations of non-normally distributed variables[74, 75] have been a mainstay for
decades. The recent success of deep learning in some applications[17, 76, 77, 78] has
put data representation into the spotlight and is, at least in part, attributed to the
underlying data representation[67, 68]. There are other common data representations,
such as dimensionality reduction[64, 65] through principal component analysis[63], and
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other techniques, such as phenotyping[79, 80], which are not even commonly thought
of as a data representations. In this work, we propose a data representation, which is
specific to the clinical domain and represents data at a high level and enriches it with
clinical knowledge.
Specifically, SEV augments the original data with a set of ordered or partially or-
dered binary variables, combining information about patients’ state from multiple per-
spectives: therapies, diagnoses, and whether or not the laboratory results or vital signs
are normal and/or achieve a typical therapeutic target. These variables are (at least
partially) ordered: the variable ‘patient is under control with first-line oral therapy’,
represents a lower severity than the variable ‘patient is not under control despite last-
line therapy’. These variables are highly interpretable, as they follow clinical reasoning
and incorporate clinical knowledge.
To make the discussion concrete, we carry out our study in the context of type 2 dia-
betes (T2D). Diabetes is a common disease with severe complications[81], affecting 29.1
million Americans[52]. T2D can be prevented or delayed through lifestyle modifications
and/or pharmacological treatment[6, 7], hence identifying patients at high risk is of high
importance. From a technical perspective, T2D is an ideal evaluation platform, as it
exhibits common challenges: T2D is heterogeneous; risk factors are correlated and not
necessarily additive; and the time frame between the risk factors and the onset of dia-
betes can be as long as 20 years, which makes missing data inevitable[82, 44, 5, 11, 10].
We encode diabetes risk factors, hyperlipidemia, hypertension, and obesity as SEVs
(a set of SEVs for each disease) and perform two clinical tasks related to type 2 diabetes.
The first task is to predict the onset of diabetes using a Cox model and the second
one is to model population heterogeneity in terms of the risk of T2D incidence using
association pattern mining. We will compare SEV to five other data presentations,
including the original data. The main objective is to study the characteristics of the
data representations.
3.2 Severity Encoding Variables
Severity Encoding Variables (SEV) is our proposed outcome-independent representa-
tion. The purpose of SEV is to summarize the numerous facets of a disease into a single
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hierarchical variable. Nodes at the same level in the hierarchy are fully or partially
ordered.
The construction of the hierarchy replicates the clinical reasoning steps of determin-
ing the severity of a certain disease. Reasoning involves a sequence of questions: (i) are
lab results and vital signs present and normal, (ii) has an intervention been initiated,
and if it has, how aggressive is it (first-line treatment, combination therapy, etc.), and
(iii) has a diagnosis been recorded. Accordingly, the first split (at the root) produces
three nodes: patient with missing, normal, and abnormal lab results. Next, we reason
about medications. Each of the three nodes can be split indicating whether treatment
has been initiated and how aggressive those treatments are. The final question splits
the nodes based on the presence of diagnoses.





























Lv 1. Control Lv 2. Detailed Control Lv 3. Tx Lv 4. Detailed Tx Lv5. Dx
Uncontrolled
TG
Figure 3.1: Sample Severity Encoding Variable hierarchy for hyper-lipidemia. Abbre-
viations used: Treatment (Tx), Diagnosis (Dx), High-density lipoprotein (HDL), Low-
density lipopro-tein (LDL), Triglycerides (TG).
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Figure 3.1 illustrates the SEV for hyperlipidemia. At the root of the hierarchy,
we ask whether lab results (LDL, HDL and TG) are normal (if they are not missing)
and which (if any) are abnormal. At the next level, we reason using medications. For
example, does a patient under control use medications? If medications are used, are
they first-line medications (statins in case of HL), other drugs, or combinations of drugs?
On the last level, we reason using diagnoses. Naturally, diagnoses are most helpful if no
other indication of disease exists.
For analysis, the hierarchy can be cut at any level and the nodes at that level are
taken as binary variables. For example, cutting the hierarchy at the top-most level
results in a set of three binary variables: ‘patient is under control’, ‘patient is not under
control’, and ‘laboratory results are missing’. These variables are partially ordered:
being under control could (but does not have to) indicate lower severity than not being
under control, but ‘lab results are missing’ is not comparable to the other two in terms of
severity. Cutting the hierarchy at the (say) third level yields 10 leaves and incorporates
information about medication use. One of these leaves would be ‘patient has abnormal
LDL despite medication’. By changing the level at which the hierarchy is cut, we can
increase the number of leaves (and information content).
SEV is a framework for representing diseases as hierarchies induced by a sequence
of clinical decisions; it is not a set algorithm for modeling all diseases. Recall that SEV
is outcome independent; once a SEV is constructed, it can be used for multiple study
end-points. The diseases that we build SEVs for are predictors of the outcome and the
construction of the SEV can (and possibly should) depend on the disease that we build
the SEV for. Depending on the disease in question, a different ordering of the same
clinical questions could yield a more clinically meaningful hierarchy, and other diseases
may incorporate altogether different questions (for example, stage and grade of cancer).
We have not observed substantial changes in predictive performance in terms of the
ordering of the questions.
Table 3.1 shows how SEV relates to other existing data representations. The table
presents a categorization of existing and the proposed data representations along three
axes: whether they are outcome-specific or outcome-independent; whether they are
dimensionality reducing or expanding; and whether they are data-driven or knowledge-
driven. All methods except SEV are data driven.
16










3.3 Materials and Methods
3.3.1 Data, Cohort Construction and Study Design
Mayo Clinic, located in Rochester, MN, provides primary care to a large population.
Resources available at Mayo Clinic are described elsewhere[83]. After IRB approval,
a cohort of 75,317 patients aged 18 or older on 01/01/2005 with research consent was
constructed. The cohort was followed from the baseline of 01/01/2005 until the end of
2015. To determine patients’ baseline status, we retrospectively collected diagnoses of
obesity, hyperlipidemia, hypertension, and prediabetes; laboratory test results for lipid
panels and fasting plasma glucose (FPG); vital signs (blood pressure, and body mass
index [BMI]); demographic information (age, gender); and medications for hypertension
and hyperlipidemia. From the cohort, we excluded patients with preexisting diabetes
at or before baseline (11,897 patients) and suspicion of diabetes (3 patients with fasting
plasma glucose > 125 ml/dL and 2 patients taking anti-diabetic drugs), resulting in a
final cohort of 63,415 patients. A description of the cohort is provided in Table 3.2.
3.3.2 Comparative representation
Severity Scores (SS): A severity score is computed for each diabetes risk factor (obesity,
hypertension, hyperlipidemia, pre-diabetes) quantifying the risk factor’s contribution to
diabetes. While all features could be combined into a single severity score (analogously
to the Framingham score), we compute a severity score for each risk factor, combining
only the features that are related to the specific risk factor. Modeling the risk factors
separately allows us to retain the relationships among them.
For each risk factor, the corresponding SS is the linear prediction from a Cox model,
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Table 3.2: Study variables for demographics, prediabetic, obe-sity, hyperlipidemia and
hypertension.
Risk Factor No. (%) of sample
Demographic
Age 41.8 ± 15.5
Sex: male 42.3 %
Prediabetic
Impaired Fasting Glucose (IFG) 2.9 %
Fasting Plasma Glucose (FPG) level, mg/dL 94.8 ± 8.5
Missing FPG 34.5 %
Obesity
Obesity 2.4 %
Body mass index (BMI) 28.0 ± 7.5
Missing BMI 34.7 %
Hyperlipidemia (HLD)
HLD 24.5 %
High-Density Lipoprotein (HDL) level, mg/dL 54.9 ± 12.3
Low-Density Lipoprotein (LDL) level, mg/dL 112.0 ± 23.9
Triglycerides (TG) level, mg/dL 130.1 ± 54.0
Missing HLD related lab 39.6 %
Statin 39.6 %
Fibrate 0.7 %
Bile-acid Resins 0.1 %
Other HLD drugs 0.4 %
Hypertension (HTN)
HTN 21.6 %
Systolic Blood Pressure (SBP), mm Hg 122.1 ± 15.8
Diastolic Blood Pressure (DBP), mm Hg 73.5 ± 9.7
Missing BP 15.1 %
ACE inhibitors 3.6 %
ARBs 1.3 %
Beta blockers 6.1 %
Calcium channel blocker 1.9 %
Diuretic 1.1 %
Antihypertensive drugs in peripheral vascular disease 0.0 %
Other HTN drugs 0.2 %
whose independent variables are the data elements that describe the risk factor in ques-
tion and the dependent variable is diabetes outcome. Missing blood pressure measure-
ments were imputed using mean imputation and a bias-correcting indicator variable
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signaling whether imputation was performed for each patient was added.
Principal Component Analysis (PCA) In this study, logistic principal component
analysis (PCA)[84] is applied to the risk factors, resulting in a single set of principal
components. We kept the first 9 principal components because additional components
are unable to explain significant amounts of variation. PCA is thus a dimensionality-
reducing, outcome-independent representation.
Deep autoencoder (DAE): For this study, we used two configurations, tuned via
cross-validation. Both used the hyperbolic tangent activation function, had two hidden
layers with 20 nodes on the first layer and had 9 and 34 nodes on the second layer,
respectively. The first configuration (DAE-9) has the lowest reconstruction error among
configurations that reduce the dimensionality of the problem, while the 34-node configu-
ration (DAE-34) has the lowest reconstruction error among all configurations. DAE-9 is
a dimensionality-reducing representation, while DAE-34 is a dimensionality-expanding
representation.
Severity Encoding Variables (SEV): A severity encoding was constructed for each
of the four risk factors of diabetes independently. The hierarchy was cut at the leaf
level, making it dimensionality-expanding (there are more nodes in the hierarchy than
original features).
3.3.3 The two tasks
Regression Analysis: The objective is to measure the impact of the data representa-
tions on the predictive performance of estimating patients’ 8-year risk of T2D. Risk
factors (lab results, vital signs, diagnoses (ICD-9 billing code rolled up into categories),
and prescriptions rolled up into NDF-RT pharmaceutical subclasses) are determined at
baseline and are transformed into the five new representations. The sixth representation
is RAW, the original (untransformed) data. Six Cox proportional hazard models are
constructed using age, gender and each of the six data representations as independent
variables. Backwards elimination is applied.
Association Pattern Analysis The central concept in association pattern mining is
an item, which is a binary variable such as ‘presence of hyperlipidemia diagnosis’ or
‘LDL ≥ 130 mg/dL’. Items are combined into conjunctive sets, called itemsets (e.g.
‘LDL ≥ 130 mg/dL AND diagnosis of hyperlipidemia’). The association of an itemset
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with the outcome is measured through confidence, which is the fraction of patients pre-
senting with the outcome among patients who present with all conditions in the itemset
(fraction of patients who developed diabetes among those with LDL ≥ 130 mg/dL and
diagnosis of hyperlipidemia in our example). Association pattern mining systematically
enumerates all itemsets and computes their confidence. In the Classification Based on
the Association (CBA) framework[85], the risk of diabetes for a patient is the confidence
of the highest-confidence rule that applies to that patient.
Continuous variables (age, severity scores, scores from PCA and DAE) are cat-
egorized into deciles (with backwards elimination discarding superfluous categories)
and laboratory results and vital signs are dichotomized using the American Diabetes
Association[86] and World Health Organization[87] cutoffs. Of interest are the number
of patterns and their predictive performance. A data representation that can achieve
higher predictive performance with a lower number of rules is preferable.
3.3.4 Evaluation Methodology
We used bootstrap estimation with 1,000 replications and paired t-tests were used to
compare the models. The evaluation metric is concordance, which is the probability
that, for a random pair of patients where one remained free of diabetes longer than
the other, the estimated risk for the patient who remained diabetes-free longer is lower.
Since all tasks were carried out using the same algorithms, the model’s ability to pre-




Figure 3.2 shows the concordance of the various data representations as box plots. The
top, middle, and bottom line in each box correspond to the upper quartile, median, and
the lower quartiles of the concordances estimated from the 1,000 bootstrap replications,
















Figure 1: Performance comparison of data representations for the
regression task.
Figure 3.2: Performance comparison of data representations for the regression task.
While all performance differences are statistically significant, some are not substan-
tial. Our population consists of relatively healthy patients, hence all methods achieved
high discrimination. A more clinically meaningful question is to accurately estimate
diabetes in risk patients who are at relatively high risk and may actually benefit from
an intervention. To this end, we consider patients with Framingham score of at least
20 and in Figure 3.3, we present the predictive performance of the Cox model on the 6
data representations on these 2,493 patients.
3.4.2 Association analysis
Association rule mining can discover an exponentially large number of patterns, many
of which can be coincidental. The parameter that controls the number of patterns is
Minimum Support in Cases (minsupC), the number of cases (patients who developed















Figure 1: Comparison of concordance on subpopulation with Fram-
ingham score ≥ 20.
Figure 3.3: Comparison of concordance on subpopulation with Framingham score ≥ 20.
number of patterns discovered as a function of minsupC.
3.5 Discussion
As the paradigm for clinical studies continues to shift toward precision medicine, the
range of tasks that clinical data analysis is used for will broaden. Since these newer
tasks may operate optimally with different data representations, understanding existing
and developing new data representations will become increasingly important. In this
manuscript, we proposed a new data representation, Severity Encoding Variables, which
represents diseases at a high level and is enriched with clinical knowledge. We compared
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Figure 1: Comparison of the predictive performance of the associ-
ation patterns discovered using the various data representations as
a function of the minimum support in cases (minsupC).
Figure 3.4: Comparison of the predictive performance of the association patterns dis-
covered using the various data representations as a function of the minimum support in
cases (minsupC).
3.5.1 Assessing the Risk of Incident Diabetes through Regression
The key concern in regression is information loss. The two dimensionality expanding
methods, SEV and DAE-34, achieved the highest performance, as they can extract more
information (e.g. SEV encodes some interactions and Deep Autoencoders can encode
non-linearities). While the performance difference between these two methods in the
entire population was minimal (although statistically significant), when we focused on
the subpopulation with very high Framingham score (20 or higher), the performance
gap widened substantially and SEV outperformed DAE by 20%. Given their high risk of
developing diabetes, this is precisely the group of patients for which we need to estimate
























Figure 1: The number of association patterns discovered using the
various data representations. (minsupC=5).
Figure 3.5: The number of association patterns discovered using the various data rep-
resentations. (minsupC=5).
Mechanistically, SEV’s performance advantage stems primarily from interactions.
It can distinguish between patients who have similar lab results at baseline but are
in very different states of severity: e.g. patients who are not yet pharmaceutically
treated are very different from those who are already undergoing combination therapy
at baseline. Despite having similar (abnormal) lab results, the latter patients are at a
disproportionately higher risk and interaction among the various facets of the disease
are required to model this correctly. Second, SEV can handle missing data without
imputation, identifying that the presence of the diagnosis code is more important in
patients who have no available lab results than in patients where the lab results already
suggest the presence of the disease.
While interactions among various facets of a disease partly explain how SEV achieves
high performance, selecting the right interactions is important. Some classification
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methods, such as decision trees or association rules, are capable of automatically dis-
covering interactions, however, as our experiment with association rules demonstrates,
finding the right combination of interactions is non-trivial.
Dimensionality-reducing data representations did not perform well. Dimensionality
reduction can reduce noise and can also lead to information loss. Given that our problem
is “tall”, the number of patients far exceeds the number of variables, dimensionality
reduction led to information loss. Among the dimensionality-reducing methods, SS takes
the diabetes outcome into account, and hence managed to preserve most of the outcome-
related information, achieving a reasonable performance with the smallest number of
features. PCA and DAE-9 are outcome-independent, and have suffered greater outcome-
related information loss than SS despite having more features.
3.5.2 Modeling Patient Population Heterogeneity through Associa-
tion Pattern Mining
On this task, SEV performed substantially (and statistically significantly) better than
others. The association mining algorithm itself performs dimensionality expansion by
forming combinations of the features the data representation provides. To find high-risk
patients, we typically focus on patterns that occur in small patient groups, which can
yield less reliable risk estimates and higher predisposition to overfitting (finding patterns
that happen to randomly coincide with diabetes). Different data representations offer
different mechanisms to reduce overfitting. The severity scores reduce the number of
items an itemset can have. For example, for SS, there are only 5 axes (demographics,
obesity, hypertension, hyperlipidemia and prediabetes), each of which is categorized into
multiple bins. Since a patient cannot fall into two different bins along the same axis,
the maximal number of conditions in a pattern is 5, which seriously limits the number
of patterns. Some patterns have as many as 11 conditions in the RAW representation.
SEV, the data representation that achieved the highest performance on association
pattern mining, applies a different mechanism. SEV uses the same dichotomization as
RAW, but SEV combined these dichotomized variables into predefined “sub-patterns”.
For instance, the SEV item ‘lipids under control’ is a combination of three RAW items:
LDL is normal AND HDL is normal AND TG is normal. These higher-level items
constrain the space of possible patterns (based on clinical knowledge) and thus reduce
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the tendency for overfitting.
3.5.3 Generalizability
We tested the data representations with a regression model and association pattern min-
ing to highlight certain characteristics of the SEV representation. We believe that these
results generalize to other classification methods, as well. First, the SEV representation
offers a high-level clinical description of the diseases enhancing clinical interpretabil-
ity of the models. Second, SEV can improve predictive performance by automatically
handling missing lab results and by incorporating clinically meaningful high-order inter-
actions. Third, as we have mentioned earlier, some methods have the ability to discover
interactions, and discovering high-order interaction is non-trivial. Currently, there are
no classification methods that can do all three well.
3.5.4 Limitations
Unlike the data-driven representations, the construction of the SEV requires clinical
expertise. Most of the effort is spent on classifying diagnoses into categories and deter-
mining pharmaceutical subclasses for drugs. This effort is not specific to SEVs; even
the RAW representation had access to these higher-level categorizations. The effort
that is specific to SEV is determining whether lab results and vital signs are normal
and whether a drug is first-line or last-line medication. This information is often readily
available from practice guidelines, such as the American Diabetes Association guide-
lines for diabetes. The effort to include this information is small, but non-negligible.
However, SEV is outcome-independent, thus once a hierarchy for a risk factor or disease
is defined, it can be used for numerous outcomes without the need to change it.
3.6 Conclusions
For both regression and association pattern mining, SEV provides the highest perfor-
mance, substantially higher than the other data representations in a high-risk subpopu-
lation, where accurate risk assessment is particularly important to appropriately target
preventive measures. Besides having the highest performance, SEV produces clinically
interpretable models and can also handle missing values.
Chapter 4
Estimation of onset time for
diseases
4.1 Introduction
The recent adoption of the electronic health record (EHR)[12, 79] provides us with an
opportunity to use it for advanced analytics. Many of these analyses rely on the onset
time of diseases. For example, accurate onset time is required for time-to-event outcome
analyses, and also for analyses that are concerned with sequences in which diseases
develop. Especially for slow-onset diseases like hyperlipidemia (HLD), hypertension
(HTN), and type 2 diabetes mellitus (T2D), onset time is not directly observable from
the EHR[11]. EHR store the time when a problem was discovered or recorded, which can
be significantly (years) different from the onset time, when the disease actually started.
In this study, we construct a model that can reliably estimate the onset time for slow
onset diseases from intermittently observable EHR data elements, most notably from
laboratory results. We demonstrate this method through estimating the onset time
of T2D from HbA1c and as a concrete application of this methodology, we use the
estimated onset time of T2D to optimize the time when a patient needs to come back
for diabetes screening.
T2D is a progressive metabolic disease, defined by chronically elevated blood sugar
levels. The American Diabetes Association (ADA)[88] defines diabetes as a condition
in which glycated hemoglobin A1c (HbA1c) levels exceed 6.5%. T2D is a fast growing
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public health concern in the United States[81]. Approximately, 29.1 million Americans
(9.3 % of the total population) are suffering from diabetes in 2014[52]. Out of 1,000
cases 7.8 are newly diagnosed this year, and this number is estimated to nearly double
to 15 out of 1,000 cases by 2050[55]. Diabetes has severe consequences, with a significant
impact on the quality of life[89, 90]. It is known to be the leading cause of kidney failure
and blindness and the seventh-leading cause of death in the United States[81]. Since
diabetes is a non-reversible progressive chronic disease[3, 4, 91], prevention and timely
diagnosis are of key importance. Early identification of patients at high risk allows for
intervention through lifestyle change or early drug therapy, which has shown to be very
effective, reducing new incidents of diabetes by 30 to 60%[6, 7].
Several diabetes guidelines[88, 92] are available for use in clinical practice. These
guidelines cover comprehensive procedures for diabetes diagnosis and management in-
cluding risk assessment[46, 93, 14, 94], intervention strategies, and timing of follow-
up visits. Despite the paramount importance of prevention, surprisingly, these guide-
lines only have loose recommendations for follow-up times for patients who are not
yet diabetic. Although there are studies that examined the follow-up times for cost-
effectiveness analysis[95] or for progression to diabetes[96], none of them addresses glu-
cose level changes over time. In our work, we aim to provide better recommendations
for follow-up times for non-diabetic patients (who naturally do not receive diabetes
drugs). A suitable follow-up time reduces waste by not requiring healthy patients to
have diabetes testing too early but it still affords the opportunity to intervene should
the patient progress to near-diabetes. As a first step, in this paper, we aim to estimate
the onset time of diabetes, the earliest time when a non-diabetic patient has HbA1c in
excess of 6.5%.
Modeling the trajectory of HbA1c from EHR data poses several key challenges. First,
patient visits are intermittent, so the actual progression of HbA1c is unobservable: we
may not be able to directly observe the HbA1c level of a patient at a particular time
t. Even though we may not be able to observe the HbA1c level directly, the patient
can still contribute partial information to the model: if the patient was out of control
(HbA1c ≥ 6.5%) at an earlier time T (T < t), then we expect the HbA1c to be out
of control at t; or if the patient was under control (HbA1c < 6.5%) at a later time T
(T > t), then the patient should be under control at t. Not all models can make use of
28
this partial information. Second, since HbA1c tends to increase over time, patients will
either become diabetic or receive preventive diabetes drugs and hence get censored. This
virtually guarantees that censoring in our study is not random. Third, some essential
data elements, most notably patient education and change in lifestyle interventions, are
missing from the structured EHR. Lifestyle interventions are the first line of defense
in both the prevention and the management of diabetes, yet related information is
unavailable in structured format in the EHR.
The natural choice for estimating onset time is by modeling HbA1c trajectory using
a linear regression model or by modeling time-to-event using a proportional hazards
model. Unfortunately, both models constructed from EHR data lack the capabilities
to address many of the above challenges. In fact, if we built a linear model to predict
HbA1c, we would erroneously find that HbA1c actually decreases over time. HbA1c
would not typically decrease without intervention; it appears to decrease because of
non-random censoring and patients undertaking lifestyle interventions. A proportional
hazards model we constructed to directly estimate the onset time of diabetes also pro-
vides poor estimates for the same reasons: the non-informative censoring assumption is
violated and the intervention is not observable and hence is unaccounted for.
In this manuscript, we propose a novel approach that uses a Bayes network[97, 98, 28]
to model HbA1c level progression in non-diabetic patients and to subsequently estimate
the optimal amount of time before a patient’s HbA1c level gets out of control. Our
model addresses all four of the above challenges. It models the (unobservable) actual
and observed HbA1c level separately. While we can only observe a patient’s HbA1c
intermittently, we can estimate the (hidden) actual HbA1c at any time. Our model
also takes partial information into account. If we observe a patient to have HbA1c in
excess of 6.5% at time T , then his latent HbA1c level is expected to be above 6.5% any
time afterwards until the patient receives intervention; and similarly, if we observe a
patient to have HbA1c level less than 6.5% at time T , we expect his latent HbA1c to be
less than 6.5% at any time before T . This separation between the latent and observed
HbA1c is the key to adjusting for non-random censoring. In addition, we include a
latent variable for the lifestyle intervention, allowing us to further reduce bias.
We evaluated the HbA1c progression model on a cohort from a large healthcare
system in the Upper Midwest United States. We demonstrated that the resultant model
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Table 4.1: Study population
Description Count
Inclusion:
Primary care patients with age 18 years or older + 157,945 = 157,945
Exclusion:
No diabetes-related observation(s) during retrospective
period.
− 87,871 = 70,074
No diabetes-related observation(s) during follow-up. − 12,826 = 57,248
Patient already presents with T2D at baseline. − 37,075 = 20,173
Not having at least two HbA1c measurements during
follow-up.
− 14,299 = 5,874
reflects the actual changes in HbA1c level well, and we also showed that the model has
the ability to accurately estimate the time to the onset of diabetes.
4.2 Materials and Methods
4.2.1 Data
A retrospective observational study design is used to construct predictive models for
glycated hemoglobin (HbA1c) level using patient’s baseline characteristics. We col-
lected clinical data from a large healthcare system in the Upper Midwest region of the
United States. Vital signs, diagnoses (ICD-9-CM) and laboratory results are available
after 2006, while medications are available after 2010. The baseline for each patient is
established on a patient’s first observation date on or after January 1, 2011. We use
a retrospective period (2006-baseline) to establish the patient’s baseline characteristics
and we track HbA1c measurement during the follow-up period (baseline-December 31,
2013) until loss to follow-up or until the patient shows indication of T2D including T2D
medication prescription, out-of-control HbA1c level (≥ 6.5) or a related diagnosis code.
The construction of the study cohort is described in Table 4.1. We include all
primary care patients aged 18 years or older at baseline (157,945 patients). We exclude
patients who do not have either HbA1c measurement or antidiabetic medications during
the retrospective (87,871 patients) or during the follow-up period (12,826 patients). The
lack of diabetes-related observations prevents us from determining the patient’s baseline
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diabetes status. We also exclude patients who are diabetic or who receive diabetes drugs
at baseline (37,075 patients), and patients not having at least two HbA1c measurements
after 2011 (14,299 patients). Type 1 diabetes patients are not included after the cohort
selection. Our final cohort has 5,874 patients.
Table 4.2: Demographics, comorbidity, and HbA1c level data at baseline
Risk Factor No. (%) of sample
Demographic
Age, mean ± SD 57.0 ± 14
Sex: male 47.2 %
Comorbidity
Hyperlipidemia (HLD) 82.3 %
Hypertension (HTN) 70.8 %
Obese (BMI ≥ 30) 55.5 %
Glycated hemoglobin (HbA1c)
Normal (< 5.7 percent) 40.8 %
Prediabetes (5.7-6.4 percent) 59.2 %
For the study cohort, we collected demographic information, diagnoses codes (ICD-
9-CM) of comorbidities, laboratory results, vital signs, and medications. The ICD-9
codes are used for identifying type-2 diabetes mellitus [ICD-9-CM 250.x0 and 250.x2],
hypertension [ICD-9-CM from 401.xx to 405.xx] and hyperlipidemia [ICD-9-CM 272.0x,
272.1x, 272.2x and 272.4x]. The American Diabetes Association (ADA)[88] guideline
is followed to determine whether an HbA1c level is normal. Normal HbA1c values
are < 5.7%. Obesity is defined as a body mass index (BMI) equal or greater than
30. All missing laboratory results are treated as normal (the physician saw no need
to order them). Since ICD-9-CM codes by themselves are insufficient to capture all
types of diseases[99, 100, 101, 102], we use phenotypes (combinations of diagnoses codes,
abnormal vital signs/laboratory results and medication usage) to identify comorbidities.
Table 4.2 presents the baseline characteristics of our cohort.
4.2.2 Bayesian network
In this manuscript, we construct a progression model for glycated hemoglobin A1c
(HbA1c) level using a Bayesian network. Bayes networks explicitly describe dependence
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relationships among variables, allowing us to incorporate our prior beliefs. Our central
prior belief is that HbA1c does not decrease without lifestyle change, therapy, or some
other kind of intervention and that prediabetic patients receive lifestyle intervention,








Figure 4.1: Glycated hemoglobin (HbA1c) level progression model.
We present the graph for our HbA1c progression model in Figure 4.1 as a template
graph. Template graphs offer a concise representation of temporal graphs, where nodes
in the large rectangle (template) repeat at every time point, while nodes outside the
template are time-independent. Clear circle nodes are observable and shaded circle
nodes are latent (not directly observable). The formulation in Figure 4.1 assumes that
Z(t) is independent of Z(τ), t 6= τ , given time t and the observed variables. This is
a reasonable assumption, because Z(t) directly incorporates t as a predictor. Time is
always measured relative to baseline in years.
Nodes X and A0 describe the patient’s baseline characteristics: A0j denotes the
observed baseline HbA1c level and Xj denotes the baseline comorbidities for patient j.
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Since baseline characteristics are measured at time 0, they are time-independent.
We model the possible intervention a patient may have received as a latent variable
Ij , which depends on the baseline HbA1c level and the baseline comorbidities. Patients
who become prediabetic (HbA1c ≥ 5.7) or suffer from multiple comorbidities are likely
to receive advice to change their lifestyle (exercise, eating habits) in order to prevent
or delay progression to overt diabetes. The fact that the patient received such advice
is not recorded in our data and whether the patient complies with such advice is also
unobservable. Specifically, we model the latent intervention variable I as
p(Ij = i | A0,j)
=

1, if i 6= i5.7 and i 6= i6.0 and A0,j < 5.7
1, if i = i5.7 and 5.7 ≤ A0,j and A0,j < 6.0
1, if i = i6.0 and 6.0 ≤ A0,j
0, otherwise
(4.1)
Note that i5.7 is the latent intervention administrated when A0 ≥ 5.7 and i6.0 is the
latent intervention administrated when A0 ≥ 6.0. We adopt two-level lifestyle inter-
vention since those who have HbA1c over 5.7[88] need to consider lifestyle intervention
and those with HbA1c over 6.0[87] receive more aggressive lifestyle intervention with
cautious follow-up schedule. Also, with increased baseline HbA1c, the effect of inter-
vention could diminish. Intervention as defined above is deterministic; it is formulated
as a probabilistic model to fit into the Bayes network framework.
In order to address the problem of non-random censoring, the cornerstone of our
methodology is the separation between the unobservable actual HbA1c level at time
t, Zj(t), and the observed HbA1c level at time t, Aj(t). We can compute the hidden
HbA1c level at any time t, while the observed HbA1c Aj(t) level is only available at one
time point Tj for each patient; it is unknown at any other time point.
We assume Zj(t) is identical to a linear combination of time t, the baseline HbA1c
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level A0,j , the patient’s baseline comorbidities Xj , and the latent intervention Ij .
p(Z(t) = z | A0, X, I = i)
=
1, if z = A0 +Xξ + tβ + i5.7δ1 + i6.0δ20, otherwise
(4.2)
where Z(t) is forced to take the value predicted by the linear model; ξ, β, and δ are
coefficients of X, t, and the interventions, respectively.
The observed HbA1C level Aj(t) of patient j at time t is identical to Zj(t) with
Gaussian noise when it is observed (i.e. Oj(t) = 1 and is unknown otherwise.
p(Aj(T ) = a | Oj(t) = o, Zj(t) = z)
=

Φ(z − a, σ2), if a = z and o = 1
1, if a is unknown and o = 0
0, otherwise
(4.3)
Notice that φ and Φ denote the probability density function (PDF) and the cumula-
tive distribution function (CDF) of the standard normal distribution. Aj(t) is unknown
at all time points t 6= Tj and needs to coincide with Zj(t) at t = Tj . We would like to
point out that this does not require Aj(t) to exactly coincide with the model prediction
from Eq (4.2); there is a Gaussian error term in Eq (4.3) that allows for differences
between the model prediction and Zj(t) and thus Aj(t).
Finally, Ej(t) = 1 denotes that patient j has had an event at time t or before,
namely there exists a time Tj ≤ t, such that Zj(Tj) ≥ 6.5.
p(Ej(t) = e | Zj(t) = z)
=

1, if e = 1 and 6.5 ≤ z
1, if e = 0 and z < 6.5
0, otherwise
(4.4)
Similarly to the intervention, Ej(t) is also deterministic; we simply use a probabilistic
notation to cast it into the Bayes network formalism.
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The separation of the actual and observed HbA1c level is the key concept of our
Bayesian network model. If the patient j already had an event, then Zj(t) must be ≥
6.5; otherwise p(Ej(t)) becomes 0. Similarly, Zj(t) must be < 6.5 for patients under
observation who will not suffer an event at Tj , i.e. Aj(Tj) < 6.5. The likelihood, which
we will discuss in the following section, becomes 0 if this assertion does not hold.
Parameters learning
In the previous section, we described the structure of our network model; this section
is concerned with estimating the values of the parameters ξ, β, δ. The maximum
likelihood estimation (MLE) is widely used for estimating the parameters of a network
model. Specifically, the data likelihood is






p(A0,j , Xj , O(t)j , A(t)j , Ej(t); ξ, β, δ)
(4.5)
where the probability density function (PDF) of the data, p(A0,j , Xj , O(t)j , A(t)j , Ej(t); ξ, β, δ),
is the marginal distribution over the latent variables Z(t)j and Ij as following:






p(A0,j , Xj , O(t)j , A(t)j , Ej(t), Zj(t) = z, Ij = i; ξ, β, δ)
(4.6)
With the probabilities of A0, X, O(t) being constant in the sense that they do not
depend on the parameters and with the probabilities of A(t), E(t), and Z(t) given in
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equations (4.2), (4.3) and (4.4), respectively, we can rewrite the PDF of the data as
p(A0,j , Xj , O(t)j , A(t)j , Ej(t); ξ, β, δ)
=

Φ(z − a, σ2), if [Ij is consistant with A0,j ] AND
[z = A0 +Xξ + tβ + i5.7δ1 + i6.0δ2] AND
[a = z and o = 1] AND
[(e = 1 and 6.5 ≤ z) or (e = 0 and z < 6.5)]
1, if [Ij is consistant with A0,j ] AND
[z = A0 +Xξ + tβ + i5.7δ1 + i6.0δ2] AND
[a is unknown and o = 0] AND
[(e = 1 and 6.5 ≤ z) or (e = 0 and z < 6.5)]
0, otherwise
(4.7)
We seek the parameter values ξ, β, θ that maximize the likelihood in Eq. (4.5) using
the PDF (4.7). Any off-the-self algorithm can be used to compute the parameters[103,
104].
Prediction
Our goal is to estimate predicted HbA1c level at time t. Since our model has hidden
nodes that we cannot observe directly, we need to find Z(t) = z that maximizes p(Z(t) |
A0, X,O(t), E(t)) for given time t. Recall that the latent intervention variables are
required for estimating Z(t), but we cannot directly observe them, thus we seek
arg max
z




[p(Z(t) = z | A0, X,O(t), E(t), I = i)× p(I = i | A0, X)]
(4.8)
4.3 Results
The goal of this work is to estimate the onset time of diseases, diabetes in our concrete
application, through modeling patients’ HbA1c trajectory via Bayesian network. Onset
time is the earliest time when a patient’s HbA1c exceeds 6.5. Unfortunately, due to the
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intermittent nature of patient visits, the actual onset time is observable only for rela-
tively few patients (492 out of 5,874). Thus we are unable to evaluate the performance
of the proposed model on the entire cohort. Instead, we evaluate our model in two parts.
In the first part, we evaluate the performance of the proposed model on the entire pop-
ulation on two related tasks, for which the outcomes are available for all patients. Our
method was not designed for these tasks, the purpose of this evaluation is merely to
demonstrate that our method can achieve reasonable performance on the entire cohort
even when we compare it to standard techniques optimized for that task. Specifically,
we evaluate the proposed model’s ability to predict HbA1c levels and compare it to a
multivariate regression model, which is the natural choice for modeling a continuous
outcome. The second task is predicting the (but not the onset time) of diabetes and
compare our method with the Cox proportional hazard model. In the second part, we
evaluate our model for the intended purpose of the algorithm, namely for predicting
the onset time of diabetes. Naturally, we can only use the 492 patients, for whom the
onset time is known. We compare our model with the Cox proportional hazards model,
using median survival time as the estimate for onset time. The 10-folds cross-validation
is used to evaluate model accuracy. All implementation and analysis is conducted with
the use of R version 3.3.1.
4.3.1 Evaluations on the Entire Population
Besides the proposed model, we built two additional models on the same cohort we
used to construct our proposed model. The first model is a multivariate linear regression
model with the observed HbA1c as the dependent variable and baseline HbA1c, baseline
comorbidities, follow-up time and the latent interventions. Analogously to the proposed
model, we considered obesity (Obese), high cholesterol (hyperlipidemia; HLD) and high
blood pressure (hypertension; HTN) as comorbidities. The second model is a Cox
proportional hazards model predicting the onset of diabetes at the end of follow-up
using the same set of independent variables as the multivariate linear regression model
(except time). Time is incorporated into the baseline hazard.
First, we interpret the models. Table 4.3, 4.4 and 4.5 shows the predictors, the
coefficients, and the empirical p-values estimated through bootstrap estimation with
1000 replications, for the three models. We interpret the coefficients of the multivariate
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Table 4.3: Predictors and coefficient estimates from the multivariate linear regression
model.
Coefficient p-value
(Intercept) 1.556 < .001
A0 0.729 < .001
time t -0.008 0.346
i5.7 0.001 0.967
i6.0 0.040 0.027
Obese 0.037 < .001
HLD -0.025 0.109
HTN 0.013 0.265
Table 4.4: Predictors and coefficient estimates from the Cox proportional hazards model.
Coefficient p-value




HLD -0.814 < .001
HTN 0.121 .382
Table 4.5: Predictors and coefficient estimates from the Bayesian network model.
Coefficient p-value
time t 0.320 < .001
i5.7 -0.089 .008
i6.0 0.298 < .001
Obese -0.048 < .001
HLD -0.098 < .001
HTN -0.074 < .001
linear regression model as follows. A unit increase in baseline HbA1c (A0) increases the
HbA1c at time t by .729; being obese increases the HbA1c at time t by .037 and receiving
the latent intervention does not change the HbA1c significantly. The other variables
can be interpreted similarly. Of particular interest is the coefficient of time: during each
additional year of follow-up time, the HbA1c level increases by -0.008, on average (i.e.
it decreases by .008). This negative coefficient is problematic for two reasons. First,
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our understanding is that HbA1c increases unless the patient receives interventions.
Second, this model cannot be used to estimate the time to onset of diabetes, because the
estimated HbA1c level is predicted to decrease over time, suggesting that the patient
will never develop diabetes. This is a clear example demonstrating the challenges of
modeling the HbA1c trajectory from EHR data. Additionally, the model obviously
contradicts clinical knowledge as well.
Table 4.4 shows the Cox proportional hazards model. The effects of coefficients can
be interpreted in the standard way: a unit increased in A0, which is a baseline HbA1c
level, is associated with 3.622 increase in the log hazard rate.
Table 4.5 shows that the coefficients for Eq (4.2) in the Bayesian network model.
The interpretation of the coefficient in the Bayesian network model is analogous to that
of the multivariate linear model: a year increase in follow-up time t increases the HbA1c
level by 0.320, on average. Assuming this rate of increase in HbA1c, a patient would
progress from almost prediabetic levels (say, HbA1c of 5.5%) to overt diabetes (HbA1c
≥6.5%) in 3 years, which is reasonably consistent with screening interval in current
guidelines[95, 88].
Estimating HbA1c level
Figure 4.2 depicts a scatter plot of observed HbA1c levels against estimated HbA1c levels
generated by the methods: the proposed Bayes network model (denoted by circles) and
by the linear regression model (denoted by crosses). The x-axis is the observed HbA1c
levels, and the y-axis is the estimated HbA1c levels. Points on the diagonal line have
no error between the observed and the estimated, and being far away from the line
indicates a larger error.
Both models offer reasonable performance; although the linear regression model has
the slightly higher correlation (.569) with the actual HbA1c values than the proposed
model (.501). We wish to emphasize that the proposed model was not designed to
provide as accurate HbA1c prediction as possible; but rather our goal was to construct
a model that is physiologically feasible and offers good prediction of diabetes onset time.
We argue that despite the small deficit in predictive performance, the proposed model
is actually better. First, as we discussed earlier, the linear model cannot predict HbA1c
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Figure 1: Scatter plot of observed HbA1c levels against estimated
HbA1c levels.
Figure 4.2: Scatter plot of observed HbA1c levels against estimated HbA1c levels.
diabetes: its prediction is that no patient will ever develop diabetes. Second, the Bayes
Network model overestimates the HbA1c levels for some patients, most prominently in
patients, for whom HbA1c levels improved over time. (These patients are in the top
left triangle of the figure.) For example, among the 259 patients for whom the Bayes
Network model overestimated the HbA1c level by more than 1 unit, the HbA1c level
actually improved, it decreased on average from 6.1 to 5.5 over 1.9 years. Again, poor
predictive performance for these patients is hardly surprising as the Bayesian network
model was constructed under the explicit assumption that HbA1c deteriorates over
time[105, 106]. For these patients, linear regression model performed better. On the
other hand, HbA1c is expected to increase in the absence of interventions[6, 7] by the
nature of the progressive disease. When patients’ observed HbA1c levels increase, the
Bayesian Network model outperforms the linear regression model. For instance, the
Bayesian network estimates HbA1c level correctly (within .2 unit difference) for 130 out
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of 414 patients who have estimated HbA1c level over 6.5.
Since the multivariate linear regression model has no ability to predict diabetic (>
6.5) HbA1c levels, we cannot use it to estimate diabetes onset time, and thus we exclude
it from further evaluation.
Estimating the Onset of Disease
In this section, we evaluate the ability of the proposed model to predict the onset of
diabetes (whether a patient develops diabetes by the end of follow-up). As we men-
tioned before, we can determine whether a patient developed diabetes by the end of
his follow-up for all 5,874 patients, but we cannot determine the precise onset time of
diabetes. We consider a patient diabetic if he has a diabetes diagnosis code or observed
HbA1c > 6.5% at last follow-up. We compared our model to the Cox proportional haz-
ards model using the concordance index (c-index)[107] as the evaluation metric. The
c-index (also known as AUC) in our case is the probability that for a randomly chosen
pair of patients, where one has developed diabetes by the end of his follow-up, while
the other has not, the patient with the disease has a higher estimated risk. For the
Bayes network the estimated risk is the estimated HbA1c; for the Cox model it is the
cumulative hazard—both computed at last follow-up. The c-statistic ranges between
0.5 and 1.0; 0.5 denotes a random model and 1.0 corresponds to perfectly discriminat-
ing predictions. The c-index value for the Bayesian network and the Cox proportional
hazards models were 0.776 (95% confidence interval: 0.754 and 0.802) and 0.736 (95%
confidence interval: 0.705 and 0.766), respectively. The confidence interval was com-
puted using bootstrap estimation with 100 replications. This result demonstrates that
the Bayesian network model has better ability to predict the onset of diabetes than the
Cox model.
4.3.2 Estimating T2D Onset Time
We now return to our original problem of estimating the onset time of diabetes, the time
when the HbA1c level exceeds 6.5. Unfortunately, for the vast majority of patients, the
onset time is not observable. We identified 492 patients who have an observed HbA1c
level between 6.3 and 6.7 and we simply call the corresponding observation time as
the observed onset time, although the actual onset time can be slightly different. We
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estimate onset time as the earliest time when a patient’s estimated HbA1c exceeds 6.5.
We can evaluate our method by comparing the estimated and the observed onset time.
We cannot expect the estimated onset time to match the observed onset time exactly.
Changes in HbA1c are not instantaneous; researchers tend to think of HbA1c as a 3-
month running average of the blood glucose level. Accordingly, our observed onset time
could differ from the actual onset time by almost 2 months (the time it takes for the
HbA1c to progress from 6.3 to 6.5 according to our model). Therefore, we believe that
the best possible estimate is within 2 months of the actual onset time. Thus these
observed onset times are not exact, but are appropriate as a “silver standard”.




















Bayes network Proportional hazards
Figure 1: The cumulative density of the prediction error in years.
Figure 4.3: The cumulative density of the prediction error in years.
Figure 4.3 shows the cumulative density distribution of the prediction error. We
computed the prediction error as the absolute difference between the predicted onset
42
time and the onset time observed from the EHR data. The x-axis represents the pre-
diction error (measured in years), and the y-axis represents the cumulative probability
of that prediction error denotes the percentage of patients who have a prediction error
smaller than the corresponding value on the x-axis. For example, 43.5% of patients
(y-axis) have a prediction error less than half year (0.5 on the x-axis). The solid black
line represents the cumulative density curve of the prediction error from the Bayesian
network. The figure shows that a quarter of the patients (22.0 %) have a prediction
error less than three months, which is our theoretical lowest error; and almost half of
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Figure 1: The cumulative density of the prediction error in years.
Figure 4.4: The cumulative density of the prediction error in years.
Figure 4.4 shows the prediction error from the Bayes network model as a function
of the observed time to onset. The x-axis represents the observed time to onset (in
years), and the y-axis represents the average prediction error for patients with that
particularly observed time to onset. The plot reveals that the Bayesian network method
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is most reliable (has the lowest error on average) when the onset time is a bit over a
year. This is reassuring because achieving half a year prediction error in patients whose
observed onset time is 3 months is trivial. Instead, most of the prediction errors are
from patients with observed onset time less than three months and longer than two
years. Patients who fall out of control within three months from the baseline could be
diabetic or almost diabetic at baseline since the HbA1c level generally does not change
much in such a short amount of time. Naturally, the uncertainty in prediction grows as
the follow-up time increases beyond 2 years.
Comparative evaluation of the proposed method
The gray dashed line in Figure 4.3 represents the cumulative density of the prediction
error from the Cox model. We use median survival time, which is the earliest time when
the survival probability is equal or less than 0.5, as the estimated onset time.
Not only does the Cox model show significantly lower prediction ability as compared
with the Bayesian network model, but it failed to make a prediction for 261 out of the
492 patients, because these patients had a survival probability higher than 0.5 at the
end of follow-up. The cumulative density of the prediction error from the Cox model
reveals that only 1.2% of the patients have a prediction error equal or less than three
months and 4.5% of the patients have a prediction error equal or less than half year.
Since the 3-year to 5-year interval is regarded as cost-effective screening interval[95], the
Cox model with 53.0% of the patients having a prediction error of more than 3-years,
has limited utility in this application.
4.4 Summary and Discussion
Electronic health records (EHR) contain rich, longitudinal, and large volumes of EHR
data, which offers us a new way of conducting clinical research. Many research questions
rely on the accurate estimation of onset time for diseases. Because of the inherent
limitations of EHR data, we cannot always directly extract this information from EHR
as they contain the recorded time for diseases rather than the onset time. For slow-onset
diseases, the onset time and the recorded time can be substantially different; they can
differ by years. In this paper, we propose a novel model to estimate the onset time of
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chronic diseases primarily based on the defining laboratory results. Additionally, we
demonstrated our model through a concrete application of estimating the onset time
of Type 2 diabetes (T2D) to optimize the time when a patient needs to come back for
diabetes screening.
While T2D management guidelines exist and address most aspects of diabetes di-
agnosis and care, including recommendations for follow-up time, they provide little
guidance for follow-up times for patients who do not have diabetes yet. Asking these
patients to visit providers earlier than necessary is wasteful; while delaying their visit
until they have developed diabetes narrows the window of opportunity for prevention.
In this paper, we take a first step towards developing recommendations for non-diabetic
patients by constructing an EHR-based model that can accurately predict the onset
time of diabetes.
First, in order to accurately predict the onset time of diabetes based on estimated
HbA1c levels, the estimated HbA1c levels need to be accurate. The model offers good
performance for patients with increasing HbA1c levels, showing less than .2 unit predic-
tion error in 130 out of 414 patients who have estimated HbA1c level over 6.5. These are
the patients who are most likely to develop diabetes in the near future and thus accu-
rate prediction is most critical for these patients. Conversely, the model did not deliver
good performance for patients with decreasing HbA1c levels, given that the model was
deliberately penalized for predicting decreasing HbA1c levels. As we mentioned earlier,
in patients prone to develop diabetes, who are exhibiting signs of insulin resistance, de-
creasing HbA1c levels are most likely a result of unobserved interventions, rather than
the natural (intervention-free) course of the disease. These patients are not at as high
risk of developing diabetes as others, thus our small prediction error is acceptable.
The performance of our model is particularly reassuring when compared to multi-
variate linear regression, the standard method for modeling continuous measures, such
as HbA1c. Linear regression, with no ability to compensate for informative censoring
(patients who are removed from the study for taking antidiabetic drugs are very likely to
develop diabetes) constructed a model that predicted decreasing HbA1c levels. Not only
is this model not supported by our knowledge of the pathophysiology of metabolic de-
generation, but it also cannot be used for predicting onset times, because the decreasing
HbA1c levels suggest that the patient will never develop diabetes.
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We further evaluated our method in terms of its ability to predict the onset time for
diabetes on a smaller cohort in which diabetes onset times are known. We found that
we could estimate the onset time within 6 months error for almost half of the patients;
and within 3 months accuracy for almost quarter of the patients. Our prediction error
was lowest for patients who progressed to diabetes in a bit over a year. Our prediction
error increased sharply for patients with an onset time 2+ years into the future. This
result suggests that the prediction model is most appropriate for prediabetic patients,
precisely the patients where correct follow-up time is most crucial.
An alternative to the proposed model could be a Cox proportional hazards model
using one of the standard methods for estimating time to onset of diabetes. Using
median survival as an estimate for time to onset of diabetes, the Cox model offered poor
performance with a prediction error in excess of 3 years for almost half of the population.
Periods between 3 to 5 years are considered cost-effective follow-up intervals[95], thus
an error of 3 years for half of the patients renders this alternative impractical.
In conclusion, we successfully developed a predictive model to estimate onset time
of chronic diseases primarily based on the defining laboratory results. We demonstrated
this method through the concrete application of estimating the optimal follow-up time
for effective T2D screening. To the best of our knowledge[108, 109], this is the first study
of modeling the trajectory of HbA1c level and estimating the onset time of diabetes.
The methodology is not specific to T2D; we believe that it can be generalized to other
slow onset diseases in a straightforward manner.
Chapter 5
Discovery of disease trajectories
towards a certain outcome
5.1 Introduction
The advent of electronic health record (EHR) systems has paved the way to perform
large-scale data analytics to uncover new medical knowledge that was previously inacces-
sible. EHR systems store information about entire populations and offer long follow-up
times. In this study, we work with data from a premier healthcare provider in the
Midwestern United States, which pioneered the adoption of EHR systems in the region,
allowing us access to nearly 13 years of follow-up time for a relatively large number of
patients. Such long follow-up, in turn, allows us to study disease trajectories that lead
to type-2 diabetes.
Type 2 diabetes (T2D) is one of the fastest growing public health concerns in the
United States[81]. There are 29.1 million patients (9.3% of the US populations) suffering
from diabetes in 2014[52]. Diabetes, which is the seventh leading cause of death in the
United States, is known to be a non-reversible (incurable) chronic disease[3, 4], leading
to severe complications[81, 5], including chronic kidney disease, amputation, blindness,
and various cardiac and vascular diseases. Early identification of patients at high risk is
regarded as the most effective clinical tool to prevent or delay the development of T2D,
allowing patients to change their life style or to receive medication earlier. In turn,
these interventions can help decrease the risk of diabetes by 30-60%[6, 7]. Many risk
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models[110, 111, 46] aiming at early identification of patients at high risk are widely
used in the clinical settings. There models typically only consider the patient’s current
state at the time of the assessment and ignore the trajectory, the sequence of events
that led up to the state.
The motivating hypothesis for our work is to study whether the trajectory influences
the risk of diabetes. Diabetes is a heterogeneous disorder involving complex biological
mechanisms. In our study, we discovered multiple trajectories to diabetes that can help
some of the underlying mechanisms and their associated risk of developing diabetes.
Access to 13 years of follow-up allows us to make inferences about trajectories leading
up to T2D. Since many diseases are progressive (worsen over time), Electronic Health
Record (EHR) data with its large sample size and long follow-up time allows us the
opportunity to study the progression of these diseases. However, due to the nature
of EHR data, unlocking this potential is challenging. The challenge stems from two
compounding factors. First, EHR data was not designed to be a research platform;
thus some critical data elements are not directly observable and need to be inferred.
Second, chronic conditions have slow onset and as a result, the onset time is not only
unobservable, but is difficult to estimate accurately. The purpose of this manuscript
is two-fold: (1) we first describe the challenges we faced in using EHR data and the
methods we developed to overcome those challenges; and (2) we then describe the
interesting findings we uncovered.
Specifically, we define trajectories as sequences in which patients develop comor-
bidities as they progress towards T2D. Besides T2D, we consider three important co-
morbidities: hyperlipidemia (HLD, high cholesterol or unbalance of the various lipids),
hypertension (HTN, high blood pressure) and impaired fasting glucose (IFG, elevated
fasting plasma glucose). We infer the typical (most frequent) trajectory and enumerate
the atypical trajectories that our data support. We build predictive models to determine
whether following an atypical trajectory is associated with different risk of diabetes.
We perform our analysis on a large community-based cohort derived from EHR
system in the Rochester Epidemiology Project[112] consisting of patients who received
their primary care at Mayo Clinic. The data has nearly 13-years of unfragmented
follow-up, making it the largest and cleanest EHR-derived data set of its kind. In this
manuscript, we show that a single typical trajectory exists and it is consistent with the
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trajectory that is commonly used for diabetes patient education. We enumerate several
atypical trajectories that cover approximately 27% of the diabetes cases observed in our
data set and assess the excess risk (if any) they confer on patients following them.
5.2 Data and challenges
5.2.1 Data
The study cohort consists of Mayo Clinic primary care patients residing in Olmsted
County, MN. During the study period from 1999-2013, when complete EHR data was
available, we have 70k patients with research consent. Informed consent was obtained
from patients during each visit and consent information was stored in the EHR. De-
mographic information, diagnosis codes encoded as ICD-9-CT, laboratory results, vital
signs and medication data were collected for this period.
5.2.2 Challenges
To establish trajectories, sequences in which the disease develop, we should only consider
new (incident) diagnoses (as opposed to preexisting conditions) along with their onset
dates. Surprisingly, this information is difficult to infer from the EHR system for the
following reasons.
Secondary Use of EHR data EHR systems were originally developed for docu-
menting patients’ state for reimbursement purposes. The presence of diagnosis codes in
the EHR are driven by billing rules. They may be present because the corresponding
condition was tested, possibly newly discovered, or was complicating the treatment of
other conditions. There is no designation in the EHR whether a diagnosis is incident or
preexisting. Moreover, diagnoses may be missing (no reimbursement was requested for
the condition) and can be false positive (the patient was merely tested for a condition).
Slow-onset conditions The second issue concerns the onset date. The development
of T2D as well as the comorbidities that commonly precede it can take decades. The
signs for these conditions are subtle and can remain undetected for years. Establishing
the onset time for these conditions is challenging. Instead of trying to estimate the onset
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Table 5.1: Study population.
Description Count
Inclusion:
Patients age ≥ 18 at 2005/01/01 + 69,747 = 69,747
Exclusion:
Diabetic patients − 389 = 69,358
Patients with unknown glucose − 14,559 = 54,717
Patients with unknown lipid − 1,023 = 53,862
Patients with unknown BP − 498 = 53,598
Non-diabetic patients who did not survive 5 years − 10,089 = 43,509
date, we only assume that it happened before the earliest recording date. Another issue
regarding the slow progression is that even with 13 years of follow-up, we can only
observe partial trajectories, that is, the development of only a few new conditions.
Therefore, if we tried to observe, rather than infer, the sequences, we would focus on
patients with the fastest progression, possibly biasing the results.
5.3 Study design
A retrospective observational study design is adapted. We use January 1, 2005 as the
baseline for our study. The period prior to the baseline, i.e. 1999-2004, is called a
pre-baseline periods. We use the pre-baseline period to determine patients’ baseline
diabetes status and comorbidities by retrospectively examining their medical history
through laboratory measurements, vitals, and diagnoses. Of particular interest is the
presence of T2D related comorbidities HLD, HTN and IFG at the baseline. We set a
follow-up period of 2005-2013 to follow the patients and record whether they developed
diabetes. The incidence of T2D and its date during the follow-up period were determined
via chart review.
The construction of the study cohort is described in Table 5.1. We included all adult
patients with research consent and no diabetes diagnosis code at baseline. There are
69,747 such patients. From this cohort, we excluded patients with a high suspicion of
diabetes (389 patients with fasting plasma glucose > 125 mg/dL or those taking diabetes
medications), unknown glucose value (14,559 patients), undetermined lipid status (1,023
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patients) and unknown blood pressure (498 patients). Our final study cohort consists
of 43,509 patients, and 4,795 of the 43,509 patients (11%) developed diabetes during
the follow-up period.
Table 5.2: Study variables for impaired fasting glucose, hypertension and hyperlipidemia
accounting for severity.
Risk Factor Description Count
Impaired fasting glucose (IFG)
ifg.no Fasting plasma glucose (FPG) ≤ 100 35,110
ifg.pre1 100 < FPG ≤ 110 6,797
ifg.pre2 110 < FPG ≤ 125 1,602
Hypertension (HTN)
htn.no No indication of hypertension 29,603
htn.untx
No drug is needed and only one blood
pressure result is elevated
5,355
htn.tx Treatment needed 8,551
Hyperlipidemia (HLD)
hld.no No indication of hyperlipidemia 12,092
hld.untx
No therapeutic need, but some indi-
cation of hyperlipidemia exists (lab or
diagnosis)
25,439
hld.tx Treatment needed 5,978
Obesity
obese.no BMI < 25 13,061
obese.overweight 25 ≤ BMI < 30 10,642
obese.obese Diagnosis or BMI ≥ 30 12,188
To determine whether a patient has a particular comorbidity at the baseline, we
use phenotyping algorithms. Phenotyping algorithms[14, 113] are simple classifiers that
infer the presence of a disease based on diagnoses, lab results, vitals and medications.
Specifically, in this study, we constructed three ordinal variables for IFG, HTN, and HLD
as combinations of diagnosis, abnormal laboratory results (or vitals) and medication.
The ADA guidelines were followed to determine whether a laboratory result (or vital
sign) is normal. Table 5.2 lists these variables and the number of patients. Except
for HLD, the majority of patients do not have a comorbidity at baseline in our cohort.
Table 5.3 presents the baseline characteristics of the remaining variables.
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Table 5.3: Baseline characteristics for variables not in Table 5.2.
Risk Factor Description Count
Demographic
age Age (mean±SD) 46 ± 16
gender Gender (% male) 42.16 %
tobacco Smoking status (past or current smoker %) 14.92 %
Diagnoses
renal Renal disease (prevalence %) 1.40 %
ihd Ischemic heart disease (prevalence %) 6.31 %
cvd Cardiovascular disease (prevalence %) 2.02 %
pvd Peripheral vascular disease (prevalence %) 1.10 %
chf Congestive heart failure (prevalence %) 0.92 %
carotid Carotid artery disease (prevalence %) 0.86 %
5.4 Methods
5.4.1 Extracting the typical and atypical trajectories
We define a diabetes trajectory as a sequence of comorbidities (i.e., HDL, HTN, and
IFG) potentially leading up to diabetes. The ordering of these comorbidities is denoted
by an arrow (→). For example, suppose we have three comorbidities A, B and C, and
the trajectory A → B → C indicates that A is followed by B and B is followed by C.
These conditions are generally assumed to follow many different sequences (trajectories).
We call the trajectory followed by most patients, typical, and label all other trajectories,
atypical.
We only know that at baseline a patient has already developed a set of comorbidities
(say) A, B and C, but we could not directly observe in which order these comorbidities
were developed. We can, however, estimate it. Suppose B follows A, A → B. If B
indeed follows A, every time we encounter B, we should also encounter A. Therefore the
probability p (A | B) should be high. Accordingly, we define the probability of A → B
as
p (A→ B) = p (A | B) (5.1)
Let us extend this to calculate the probability of an entire trajectory. We define the
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probability of a trajectory as the likelihood of observing the data set under the as-
sumption that it was generated by the trajectory in question. Suppose there are four
comorbidities A, B, C and D, and the trajectory is A → B → C → D. Patients
following this trajectory may have progressed to different stages: some patients may
have progressed all the way to D, others to C, some to only A or B, and yet others
may not present with any symptoms yet, but will follow the trajectory once they start
progressing. In patients, who have already progressed to D along this trajectory, we
should see A, B and C with very high probability, i.e. p (A,B,C | D) should be high.
In other patients following the same trajectory, who have only progressed to C, we
should see A and B with high probability, i.e. p (A,B | C) should be high. We define
the probabilities for patients who have only progressed to A or B analogously, giving
us the probability of the trajectory as
p (A→ B → C → D) = p (A,B,C | D)× p (A,B | C)× p (A | B) (5.2)
Note that the same patient can be counted multiple times. For example, a patient pre-
senting withA andB at baseline, is counted not only for the sequence p (A→ B → C → D),
but also for p (A→ B → D → C), as well as for p (B → A→ C → D) among others.
Therefore, the likelihood does not coincide with the percentage of patients following this
trajectory.
5.4.2 Type 2 diabetes risk modeling with trajectories
To address the association between the different trajectories and the risk of developing
diabetes, we constructed a multivariate logistic regression model for diabetes outcome
using demographics (Table 5.3), glucose level, staged comorbidities (Table 5.2), as well
as three trajectories (Table 5.5). Data analysis was conducted in R version 3.2.3.
5.5 Results
In this section, we show the typical trajectory extracted from our data and subsequently
enumerate the atypical trajectories. We then investigate whether the atypical trajecto-
ries are associated with increased risk of developing T2D.
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5.5.1 The typical trajectory
Table 5.4: The five most likely trajectories.
No. Trajectory Likelihood
1 HLD → HTN → IFG → T2D 0.100
2 HLD → HTN → T2D → IFG 0.067
3 HLD → IFG → HTN → T2D 0.058
4 HTN → HLD → IFG → T2D 0.044
5 HLD → IFG → T2D → HTN 0.040
Table 5.5: Typical and atypical trajectories.
No. Trajectory HLD HTN IFG Count T2D p(T2D)
1 Typical N N N 8,795 235 0.037
2 Typical Y N N 16,307 948 0.058
3 Typical Y Y N 8,297 950 0.115
4 Typical Y Y Y 3,485 1,362 0.391
5 Atypical with skipping HLD N Y N 1,711 92 0.054
6 Atypical with skipping HLD N Y Y 413 84 0.203
7 Atypical with skipping HTN Y N Y 3,328 992 0.298
8
Atypical with skipping HLD
and HTN
N N Y 1,173 132 0.113
In Table 5.4, we present the five most likely trajectories, selected based on the
likelihood. The likelihoods are generally low, because the probability of progression
to T2D itself is low. The most likely trajectory in our study cohort is p(HLD →
HTN → IFG → T2D), which coincides with the trajectory that is commonly used for
patient education. We also observe the most likely trajectory is far more likely than the
others. Counting the number of patients (Table 5.5) who show no evidence of following a
different trajectory confirms that the vast majority of the patients follow this trajectory.
This satisfies our definition of typical trajectory.
5.5.2 Atypical trajectories
There is evidence in our data that patients can follow trajectories different from the typ-
ical one (i.e., p(HLD → HTN → IFG → T2D)). In our definition, a patient is said to
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follow a trajectory p(HLD→ HTN→ IFG→ T2D), if and only if his sequence of comor-
bidities are constant with that trajectory. Formally if the patient has k comorbidities,
these have to coincide with the first k diseases along the trajectory. A patient follows
the typical trajectory if his comorbidities are consistent with the typical trajectory; and
follows an atypical trajectory if he shows evidence to contrary. For example a patient
with comorbidities {HLD, HTN} follows the typical trajectory we identified, while a pa-
tients with comorbidities {HLD, IFG} shows evidence to contrary, i.e. skipped “HTN”,
because HTN preceded IFG along the trajectory. A patient who has no comorbidity is
assumed to follow the typical trajectory. We enumerate the atypical trajectories based
on which conditions of the typical trajectory are “skipped”.
Table 5.5 shows the typical and atypical trajectories with detailed information. Each
row in the table corresponds to a patient group, presenting with a set of comorbidities
at baseline. Patients with T2D at baseline are excluded, so we omit T2D from the
table. The column “No.” is simply an arbitrary identifier assigned to the group. We
also show the total number of patients in this group and the number of cases, patients
who developed T2D during the follow-up period. We assign these patient groups to
trajectories, which we also show in the table. For instance, we assign No. 7 group
to the atypical trajectory. Patients in group No. 7 present with HLD and IFG but
not with HTN. We do not know whether they developed IFG or HLD first, but it is
inconsequential: the fact that they have IFG and no HTN offers evidence that they did
not follow the typical trajectory. In the typical trajectory, patients develop HTN before
they develop IFG; thus, every patient with IFG should also present with HTN.
The number of patients who followed atypical trajectories is substantial. From the
table, we can see that 6,626 of the 43,509 patients (15%) followed atypical trajectories;
and more importantly, 1,300 of 4,795 (27%) cases (patients who developed T2D) followed
atypical trajectories.
5.5.3 Atypical trajectories and the risk of developing type 2 diabetes
To study whether the trajectory influences the patients’ risk of progression to diabetes,
we have built a regression model for incident diabetes which, besides the usual comor-
bidities, also includes the trajectory as an independent variable. Table 5.6 shows the
predictors and their coefficient estimates. The predictors describing HLD, HTN, IFG
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Table 5.6: Predictors and coefficient estimates from the type 2 diabetes predictive model.
Variable Coefficient estimate (SE) p-value
(Intercept) -13.55 (0.44) <.001
age 0.01 (0.00) <.001
male -0.16 (0.39) <.001
gluc 0.11 (0.00) <.001
hld.untx 0.38 (0.08) <.001
hld.tx 0.29 (0.09) <.001
htn.untx 0.19 (0.07) .005
htn.tx 0.26 (0.06) <.001
ifg.pre1 0.20 (0.07) .005
ifg.pre2 0.00 (0.12) .978
obese.ovrwght 0.10 (0.05) .048
obese.obese 0.45 (0.05) <.001
trajskip.htn 0.24 (0.08) .002
trajskip.hl -0.06 (0.13) .650
trajskip.both -0.54 (0.16) <.001
and obesity are ordinal; their levels are ordered: “no” (no sign of disease) is less severe
than “untx” (no treatment needed) and “untx” is less severe than “tx” (treated). The
effect of each level is measured relative to the next lower level. For instance, the effect of
hld.tx is measured relative to hld.untx: requiring treatment for hyperlipidemia (hld.tx)
increases the log odds of progression to diabetes by .29 relative to patients who do not
require treatment for hyperlipidemia (hld.untx).
Two of the atypical trajectories are significant. The atypical trajectory where pa-
tients skip HTN (patients with HLD and IFG but without HTN) increased the log odds
of developing T2D by 0.24 compared to the typical trajectory. At first, this appears as
if the lack of HTN increased the risk. The risk of T2D depends on the deterioration
of the underlying metabolic health and the comorbidities, including HTN, are imper-
fect indicators of the deterioration of the metabolic health. One probable explanation
is that the metabolic health of the patients with HLD and IFG (but without HTN)
has deteriorated just as far as that of the patient with HTN, but their blood pressure
has not yet increased sufficiently to meet the HTN diagnosis criteria. In such patients,
the deterioration of the underlying condition, which typically manifests itself in the
HTN disease, cannot contribute to the diabetes risk through the HTN variable, but its
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detrimental effect is captured through the trajectory variable.
The atypical trajectory where patients skip both HLD and HTN altered the log
odds of developing T2D by -0.54 (i.e. decrease it by .54) as compared to the typical
trajectory. In patients following the typical trajectory, IFG increases the (log odds
of the) risk of diabetes by .20 or by .20+.00=.20 depending how far the patient has
progressed. However, in the absence of both HLD and HTN, these .20 overestimate the
patients’ actual risk, thus the trajectory adjusts the risk (downwards). In other words,
for patients who neither present with HLD nor with HTN, elevated fasting glucose is
not as damaging (with regard to diabetes) as we would expect assuming that IFG is
independent of these conditions.
5.6 Discussion
In this work, we studied a novel approach to infer disease progression from Electronic
Health Records (EHR). EHR with their large sample size and long follow-up time are be-
coming increasingly popular for population-based disease progression studies. However,
unreliable diagnostic codes in the EHR data combined with the slow onset of many of
the chronic diseases make it virtually impossible for us to directly observe trajectories,
sequences in which the diseases develop. In this work, we described methods to sidestep
or overcome these issues and discover interesting, previously unknown knowledge.
Specifically, we overcame the problem of unreliable diagnostic codes through phe-
notyping. Phenotyping refers to the combined use of diagnosis codes, lab results and
medications to determine whether a patient presents with a condition at a given time.
As phenotypes, we created an ordinal variable for each condition of interest, which,
besides indicating the presence of a condition, also encoded its severity.
Solving the issue of onset dates is more challenging and we sidestepped it by simply
assuming that the onset date occurred before the earliest recording date. Even if we
managed to estimate the onset dates accurately, the pre-baseline period (and the 13
years of follow-up in general) was insufficient to observe entire trajectories. Instead of
directly observing, we inferred the trajectories from snapshots. We used likelihood esti-
mation to find a typical trajectory, which coincided with the trajectory that is commonly
used for diabetes patient education.
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We found that in the context of diabetes, some atypical trajectories had significant
effect on the risk of progression to T2D. We observed that “skipping” HTN increased
the risk of T2D by approximately the same amount as HTN itself; and we also observed
that having high blood glucose without HTN or HLD is not as damaging as one would
expect under the assumption that these conditions affect the risk of T2D independently.
These are novel findings that were previously not known and not even studied.
Given the popularity of EHR data as a research platform, we expect larger sample
sizes and longer follow-up times in the future. With the explosive growth of wearable
health devices providing real-time physiological measurements, we may be able to infer
the onset dates with better accuracy. Unfortunately, these improvements will not be
able to completely eliminate the issues addressed in this work. The need for using
historic data will remain and along with it the uncertainty in the historic data will
remain, as well. Methods such as the ones proposed in this paper will still be required
to help unlock the full potential of historic data.
Chapter 6
Discovery of multiple disease
trajectories
6.1 Introduction
Disease trajectories[11], the order in which diseases develop, is an important problem in
medical research. Multiple ongoing initiatives encourage the inclusion of a broad range
of patient information into clinical decision making. Disease trajectories are an example
of such currently underutilized but useful information. Recent studies showed that
patients who share the same risk factors at an encounter, can experience substantially
different outcomes[114, 115, 10] and these differences could be partially explained by
the patient’s progression patterns[11, 116] before the encounter in question. While this
suggests that trajectories are valuable for the effective prevention and management
of diseases[117, 118], currently there are no algorithms specifically to extract disease
trajectories from electronic health records (EHR) data.
Computational methods that can be adapted to incorporate sequential information
into clinical studies exist[35, 36, 37, 38, 39]. Sequential pattern mining (SPM)[26] is
the most promising such method. The goal of SPM is to extract all sequences and
their subsequences from a database of events. While SPM can extract sequences of
clinical events (e.g. diseases, phenotypes, disease severity indicators[119, 120]), due
to its fragmented nature, EHR data does not contain full trajectories; we can only
extract partial trajectories. SPM offers no facility to combine partial trajectories into
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full trajectories. In addition, SPM suffers from a tendency to yield an exponentially
large number of trajectories. Although each trajectory is self-explanatory, the sheer
number of them can ultimately render the results uninterpretable.
Causal structure discovery (CSD)[27, 28] offers an alternative approach to trajectory
inference. Given a set of observations described by features (variables), the goal of
CSD is to construct a partially directed graph with nodes representing features and
edges representing causal relationships between the nodes they connect. The edges
are oriented in the direction of cause to effect if this direction can be inferred. The
problem with this approach for learning trajectories is twofold. First, it does not give
us trajectories; it gives us a causal graph, from which we have to extract trajectories.
Second, causality is neither required nor sufficient for explaining sequences of clinical
events. For example, multiple diseases can have a latent common cause and these
diseases can represent different stages of deterioration. These diseases do not cause
each other but are associated, have a definite temporal ordering, and can be predictive
of the next disease the patient is going to develop.
In this work, we focus on the development of a novel computational method specifi-
cally for learning disease trajectories from EHR data. These trajectories are sequences
of clinical events (phenotypes or disease diagnoses) that have a definite temporal order-
ing along the trajectory and are associated with each other (but do not have to cause
each other). The resulting set of trajectories have to be able to explain the observed
clinical events.
Specifically, we have three key contributions. First, we propose a trajectory ex-
traction algorithm. Inspired by sequential pattern mining, the proposed extraction
algorithm extracts partial sequences from EHR data and combines them into full tra-
jectories. Second, we develop filtering criteria based on the association and precedence
of pairs of successive clinical events. Third, we propose a likelihood function for trajec-
tories assessing the risk of developing a set of outcomes given a set of trajectories. The
likelihood function is used to evaluate the goodness of fit of a set of disease trajectories.
We applied the proposed method in the context of Type 2 Diabetes (T2D) and
its complications. T2D is a growing public concern in the United States[1]. 9.4% of
the US population was reported to have T2D in 2015[2]. It is the 7th leading cause
of death in the US[1] with accompanying severe chronic diseases including macro and
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microvascular diseases[1, 5]. Since T2D and associated complications are progressive and
non-reversible[3, 4], early identification and appropriate interventions are important[6,
7]. This makes T2D and its complications an ideal application to demonstrate our
proposed methods.
EHR data of 53,409 patients at Mayo Clinic[83] were used as a development cohort.
Diabetes trajectories were extracted and internally validated in terms of their ability
to explain the observed partial trajectories. External validation was then performed on
EHR data of 59,686 patients from an independent health system, M Health Fairview.
The remainder of this manuscript is organized as follows: in Section 6.2, we describe
the data that are used in this study, present the proposed methods, and describe how
we evaluated the models; in Section 6.3, we demonstrate and evaluate our proposed
approaches on real EHR data; and in Section 6.4, we discuss the results.
























































































































































































































































































































































































































































































































































































































































































































































































































































A retrospective observational study was conducted. We utilized two large cohorts
of 53,409 Mayo Clinic and 59,686 M Health Fairview primary care patients aged 18 or
over in 2005. We collected patients’ medical histories, including demographics, diagnosis
codes, vital signs, laboratory test results, and prescriptions. Patients’ medical history
is segmented into two distinct three-year windows (2005-2007 and 2012-2014) with a
four-year inter-window gap. We use the first window as the baseline of our study, and
the second window as a follow-up period to see the disease progressions. Phenotypes
were identified within each window in a cumulative manner: chronic conditions present
in the baseline window are carried forward to the follow-up window. Table A.1 in the
Appendix lists the precise definition of the phenotypes. Table 6.1 describes the cohorts
in each window.
6.2.2 Trajectory discovery
Let V = {v1, . . . , vN} be a set of all events in the EHR data where each event v represents
a phenotype or a disease from Table 6.1, and N is the number of total phenotypes. In
the followings, we use the terms events, diseases, and phenotypes interchangeably. A
trajectory τ is a sequence of events
τ = v1 → v2 → · · · → vl
where→ denotes temporal succession: the event on the left-hand side is followed by the
event on the right-hand side. We assume that each patient follows a single trajectory.
Let x
(t)
i be an observation vector of all events in V for a patient i in time window t.
Specifically, x
(t)
i,j = 1 indicates whether the patient i has developed the event (disease)
vj during or before the time window t while x
(t)
i,j = 0 indicates that the patient i has had
no indication of the disease vj during or before the time window t. For convenience, we
denote x
(t)




i,j = 0 as x
(t)
i,j respectively. Since all diseases are progressive
and non-reversible, x
(t)
i,j = 1 implies x
(t+1)
i,j = 1 for all t.
Patient i follows a trajectory τ if and only if for all time t during the study period,




of events that patients had developed by time t is identical to
the first ‖s‖ diseases on the trajectory τ .
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Algorithm for extracting disease trajectories from EHR data
The proposed extraction algorithm obtains a trajectory set by concatenating progression
pairs. A progression pair ρ is an ordered pair of a (potentially empty) set s of events and
a single event v, ρ = (s, v). In our application, s represents the set of diseases the patient
has developed in or before the baseline window and v is a disease newly developed in the
follow-up window. In our application, s represents the set of diseases the patient has
developed in or before the baseline window and v is a disease newly developed in the
follow-up window. Patients can develop multiple new diseases in which case multiple
progression pairs are produced.
Trajectories are built up iteratively, concatenating two progression pairs in each
iteration. Two progression pairs, ρ1 = (s1, v1) and ρ2 = (s2, v2), can be concatenated
into s1 → v1 → v2 if and only if s1 ∪ {v1} = s2. Initially, we consider progression pairs
ρ = (φ, v1) where v1 ∈ V and φ represents an empty set (patient has no diseases in the
baseline window). Next, we extend the trajectory using the progression pair ({v1} , v2)
yielding a trajectory v1 → v2; then we further extend it using the progression pair
({v1, v2} , v3) into v1 → v2 → v3, continuing until no applicable progression pair can be
found. Algorithm 6.1 formally describes the process.
Criteria for filtering disease trajectories
The objective of the filtering criteria is to introduce the constraints that specify the
relationship between two adjacent events on a disease trajectory. Consider a trajectory
τ = v1 → · · · → vm → vn → . . . , and two temporally ordered events, vm and vn, vn
follows vm. We introduce three heuristic-based criteria that capture the relationship
between two successive events as follows:
 Association: vm and vn are temporally associated given τ if and only if developing











n | v(0)m , v(0)n , τ
)
.
 Strict precedence: vm precedes vn given τ if and only if among patients with both
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Algorithm 6.1: Extracting disease trajectories from EHR data
Input: X(0), X(1), threshold
Output: T
Function ExtractProgressionPairs(X(0), X(1), threshold):
S := distinct events on X(0)
for s ∈ S do
for v ∈ V do
ρ := (s, v)
if σ(ρ,X(0), X(1)) > threshold then





Function GrowTrajectories(τ , P, T):
P′ := {∀ρ = (s, v) | (ρ ∈ P) ∧ (s = {v | v ∈ τ})}
if P′ 6= φ then
for ρ ∈ P′ do
τ ′ := . . .︸︷︷︸
τ
→ v where v is in ρ = (s, v)
T := GrowTrajectories(τ ′,P,T)
end
else
T := T ∪ {τ}
end
return T
Function ExtractTrajectories(X(0), X(1), threshold):
P := ExtractProgressionPairs(X(0), X(1), threshold)
T := φ
for v ∈ V do
if (φ, v) ∈ P then
τ := φ→ v
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.
Partial precedence differs from strict precedence in that it allows for the two prob-
abilities to be statistically equal, meaning that vm and vn developed concurrently.
A trajectory is filtered out if any two successive events on the trajectory do not
satisfy the criteria. One or more criteria can be applied at the same time. Specifically,
we will consider the following combinations: association (A), strict precedence (PS),
partial precedence (PP ), association and strict precedence (A&PS), association and
partial precedence (A&PP ). Note that we do not apply strict precedence and partial
precedence at the same time.
Likelihood function for assessing the risk of developing a set of outcomes
along a trajectory
The (partial) likelihood, the joint probability of observing the outcomes (presence or
absence of all diseases in the follow-up window) given the baseline diseases and a set of
trajectories, is key to assessing the goodness-of-fit of the trajectory set and for ranking
the trajectories. The need to define a new likelihood arises because (i) outcomes are not
independent of each other, (ii) the dependence structure among the outcomes depends on
which trajectories the patient follows and (iii) we may not be able to uniquely determine
at baseline which trajectory the patient follows, and (iv) the dependence structure is
simple since the trajectories are sequences.




i denote the state of all diseases (present or absent)
for patient i in the baseline window and in the follow-up window, respectively. We
can partition x
(1)





i = {pi, ni, f̄i, ūi, ei},
where pi is the set of diseases that patient i developed in or before the baseline window
(pre-existing), ni is the set of diseases patient i newly developed in the follow-up window
(new), fi is the set of diseases the patient is likely to develop along the trajectory in
the future (future), ui is the set of diseases that the patient is not expected to develop
along this trajectory (unlikely), and ei is the set of diseases that the patient was not
supposed to develop following trajectory τ (error). The bar above fi and ui indicates
that none of these diseases is present in the follow-up window. If the patient indeed
follows τ , ei is empty.
The probability of observing the set of follow-up diseases (described by x
(1)
i ) given
the baseline disease states x
(0)






= Pr(pi, ni, f̄i, ūi | x(0)i , τ)
= Pr(pi | ni, f̄i, ūi, x(0)i , τ)× Pr(ni | f̄i, ūi, x
(0)
i , τ)×




= Pr(pi | x(0)i )× Pr(ni | x
(0)
i , τ)×
Pr(f̄i | ni, x(0)i , τ)× Pr(ui | τ)
(6.2)
= Pr(ni | f̄i, x(0)i , τ)× Pr(f̄i | x
(0)
i , τ) (6.3)
Eq. (6.1) follows from the chain rule of probabilities and assumes that ei is empty.
If ei is not empty, we handle it later as an error condition. Eq. (6.2) holds true for
the following reasons. First, pi, the set of pre-existing diseases, only depends on the
baseline disease states x
(0)
i (in the absence of errors). Since these are chronic diseases,
which can be controlled but not cured, Pr(pi | x(1)i ) = 1, which we use in Eq. (6.3). As
patients progress from the baseline diseases along the trajectory τ , they develop the new
diseases ni during the follow-up, leaving f̄i to develop later. Accordingly, ni depends
on the trajectory τ , the baseline disease states x
(1)
i and f̄i showing how far along τ the
patient progressed. Once we account for the dependence between ni and f̄i, f̄i only
depends on τ : the set of diseases that are possible along τ . Similarly, ūi, the set of
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diseases that are not possible along τ only depend on the trajectory and Pr(ūi|τ) = 1,
which we use in Eq. (6.3).
The two terms in Eq. (6.3) can be computed as follows. With ni = {ni,1, ni,2, . . . , ni,k},
where diseases are indexed in the same order as they appear on the trajectory τ ,
Pr(ni | f̄i, x(0)i , τ)
= Pr(ni,1 | f̄i, x(0)i , τ)×
Pr(ni,2 | ni,1, f̄i, x(0)i , τ)× · · ·×
Pr(ni,k | ni,1, . . . , ni,k−1, f̄i, x(0)i , τ).
The first new disease, Pr(ni,1 | f̄i, x(0)i , τ) can be directly observed from data. When
patients develop multiple new diseases, subsequent new disease probabilities Pr(ni,k |
ni,1, . . . , ni,k−1, f̄i, x
(0)
i , τ) (k ≥ 2) are approximated as if the patient had already devel-
oped ni,1, . . . , ni,k−1 by baseline.
Finally, the last term in Eq. (6.3) is computed as
Pr(f̄i | ni, x(0)i , τ) = Pr(f̄1 | ni, x
(0)
i , τ),
where f1 is the first disease in fi along τ . If the patient has not progressed to f1 along
τ , then Pr(f̄j | f̄1, τ) = 1 for all subsequent (j ≥ 2) diseases along the trajectory.
Errors in trajectory assignment When the patient is assigned an incorrect trajec-
tory, we may find that ei is not empty or that some of the diseases along the trajectory




i , τ) to be close to 0, indicating that
the follow-up disease states are impossible given the trajectory.
Under-determined trajectory assignment Multiple trajectories may share a com-
mon prefix therefore it may not be possible to assign the patient to a unique trajectory
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i , τ) from Eq. (6.3) otherwise
and Pr(τ | x(0)i ) is determined from the training data as the proportion of patients who
end up following τ in the follow-up window among those who share the same baseline
disease state x
(0)
i . In computing Pr(τ | x
(0)
i ), patients for whom the trajectory cannot
be uniquely determined even in the follow-up window are ignored.
Likelihood The likelihood of the trajectory set T given the baseline and follow-up








i , T ) (6.5)
using eq. (6.4). Note that this is a partial likelihood since we do not compute Pr(x
(0)
i ).
We chose not to compute it because the trajectories are based on observed changes in
disease states and such changes cannot be reliably observed before the baseline.
Ranking Algorithm We rank disease trajectories using the forward selection method.
We begin with an empty set of trajectories, and repeat, including the most significant
trajectory, i.e., the trajectory that can maximize the likelihood most, into the set until
there is no trajectory available. We rank in the order of inclusion.
6.2.3 Competing trajectory extraction methods
Although ours is the first method specifically for extracting disease trajectories from
EHR records, for comparative evaluation, we propose three adaptations of Bayes net-
work structure discovery algorithms to trajectory discovery.
 BN-I (Causal inference-based method): The causal network (graph) is learned by
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the max-min hill-climbing (MMHC) algorithm[121] and trajectories are extracted
by a depth-first traversal of the graph.
 DBN-I (Causal inference-based method): We apply a Dynamic Bayes Network
(DBN) structure learning algorithm to the data and extract trajectories through
depth-first traversal of the unrolled graph[122, 123].
 DBN-G (Generative model-based method): We discover the causal network from
the original data using the DBN discovery algorithm (as we did for DBN-I). Then
we generate synthetic data from the DBN[124] containing full trajectories, and
finally, we extract full disease trajectories directly from synthetic sequential data.
6.2.4 Experimental setup
We evaluate the trajectory sets based on their ability to explain the diseases observed
in the follow-up window (follow-up diseases) given the diseases in the baseline window
(baseline diseases) and the set of trajectories. We use the log-likelihood as the metric of
how well a trajectory set explains the follow-up diseases. If a trajectory is correct and
can “predict” the subsequent diseases (i.e. follow-up diseases) correctly, the probability
of observing the set of follow-up diseases is high, resulting in a small negative log-
likelihood; otherwise, the follow-up disease set is unexpected and the probability is low
(resulting in a large negative log-likelihood).
Evaluation method
Internal evaluation. We generated 1,000 datasets via bootstrap resampling on the
Mayo Clinic (MC) data. Each bootstrapped dataset consists of a training set and an
out-of-bag test set. Trajectories were extracted from the training set and evaluated
on the out-of-bag test set. External evaluation. Trajectories were extracted from
the 1,000 bootstrap replicas of the MC data set and evaluated on the entire FHS data
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Figure 6.1: An overview of the experimental setup.
Experiments
We conduct three experiments in total. First, we evaluated the Proposed method (with-
out filtering) and the three comparison algorithms on extracting disease trajectories from
EHR data. This experiment results in four sets of trajectories, each set named after the
algorithm that produced it: Proposed, BN-I, DBN-I, and DBN-G. We evaluate the four
trajectory sets using log-likelihood as the metric internally and externally as described
previously.
These algorithms can potentially produce large trajectory sets, impeding interpre-
tation. Next, we use the proposed ranking algorithm to select the top n trajectories
(n = 1, . . . , 20) and evaluate the resulting n trajectory sets (for each algorithm) as
described above. Only the training data is used for ranking.
Third, we evaluate the proposed filtering criteria. Six trajectory sets are obtained
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after applying combinations of filtering methods to the disease trajectories produced
by the Proposed method as follows: unfiltered (U), association (A), strict precedence
(PS), partial precedence (PP ), association and strict precedence (A&PS), association
and partial precedence (A&PP ). We follow the same evaluation process as above. Figure
6.1 describes an overview of the experimental setup.
6.3 Results
6.3.1 Evaluation of the algorithms for extracting disease trajectories





Mayo Clinic Fairview Health Services
Proposed 5,005 -4.20 ( -4.30, -4.10) -5.73 ( -5.85, -5.60)
BN-I 76 -20.95 (-21.13, -20.71) -22.62 (-22.80, -22.47)
DBN-I 79 -20.49 (-20.68, -20.25) -22.93 (-23.10, -22.76)
DBN-G 63 -9.14 ( -9.31, -8.99) -11.43 (-11.61, -11.24)
First, we evaluated the four algorithms (Proposed, BN-I, DBN-I, and DBN-G) for
extracting disease trajectories from EHR data. Table 6.2 shows the number of trajecto-
ries in each trajectory set extracted from the Mayo Clinic (MC) data, the log-likelihood
of the trajectory sets along with the 95% confidence interval on the MC data and ex-
ternally on the M Health Fairview (FHS) data. Table 6.2 reveals that Proposed shows
the highest log-likelihood, followed by DBN-G, and BN-I and DBN-I.
Some of the algorithms discovered very large sets of trajectories, hindering expert in-
terpretation. We evaluated the four algorithms based on their performance on a smaller,
more readily interpretable, set of trajectories. Figure 6.2 depicts the log-likelihood of
the top n trajectories, n = 1, · · · , 20. Each color and line type represents a different
extraction algorithm and filtering criterion. The lists of the top 20 disease trajectories
obtained by the four extraction algorithms can be found in Table A.2 to A.5 in the Ap-
pendix. In Figure 6.2 (left), Proposed shows the highest log-likelihood over the entire
range of n on the MC data. DBN-G shows the same log-likelihood as the Proposed
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Extraction Proposed BN-I DBN-I DBN-G
Filtering U A PS PP A&PS A&PP
Figure 1: The log-likelihood of top n disease trajectories explaining
the disease progressions most.
Figure 6.2: The log-likelihood of top n disease trajectories explaining the disease pro-
gressions most.
on the top (one) trajectory while the difference in log-likelihood between Proposed and
DBN-G keeps increasing as we include more trajectories. BN-I and DBN-I show the
lowest log-likelihood over the entire range. The top (one) disease trajectory on BN-I
and DBN-I shows approximately 2.7 to 3.3 lower log-likelihood (e3 = 20 times lower
likelihood) than Proposed.
The slopes of BN-I, DBN-I, and DBN-G become flat after the top 4 to 12 trajectories
while the slope of Proposed remains steeper, indicating that additional trajectories can
help Proposed but not the three competing methods. Specifically, the increase in the
log-likelihood as a result of adding an extra trajectory becomes less than 1.0% after the
top 4 trajectories for BN-I and DBN-I, and the top 12 trajectories for DBN-G, while
for Proposed, the change in log-likelihood is greater than 1.0% even after the top 20
trajectories. Using the top 20 trajectories, Proposed shows approximately 2.6 to 14.6
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higher log-likelihood than BN-I, DBN-I, and DBN-G.
6.3.2 Evaluation of the filtering criteria
Table 6.3: The number of disease trajectories obtained after applying combinations of





Mayo Clinic Fairview Health Services
U 5,005 -4.20 (-4.30, -4.10) -5.73 ( -5.85, -5.60)
A 334 -5.42 (-5.54, -5.29) -6.89 ( -7.02, -6.76)
PS 31 -9.08 (-9.24, -8.92) -10.50 (-10.68, -10.33)
PP 778 -6.93 (-7.08, -6.79) -7.67 ( -7.80, -7.51)
A&PS 26 -9.40 (-9.57, -9.23) -11.01 (-11.20, -10.84)
A&PP 43 -8.11 (-8.27, -7.95) -8.69 ( -8.84, -8.52)
Rather than taking the top n trajectories, a more flexible way of reducing the number
of trajectories and thus improving interpretability is to use the proposed filtering criteria.
Six combinations of the filtering criteria (U the set of unfiltered trajectories, A, PS , PP ,
A&PS , and A&PP as defined in Section 6.2.2) yielded six trajectory sets. For each
trajectory set, Table 6.3 shows the number of trajectories, the log-likelihood with its
95% confidence interval internally on the MC data and externally on the FHS data. The
use of filtering criteria achieved a substantial reduction in the number of trajectories
(80% to 100-fold reduction), at the cost of reducing the log-likelihood by only 1.2 to
5.2. Among the filtered set of trajectories, A&PS has the lowest (worst) log-likelihood,
which is still 10 higher than BN-I or DBN-I. The log-likelihood of A&PS is comparable
to the third competing method, DBN-G, but achieves this similar performance (-9.4 vs
-9.1 on MC) with 55% fewer trajectories (26 vs 63).
6.3.3 Trade-off
Figure 6.2 shows that an increasing number of trajectories typically yields better log-
likelihood but impedes interpretation. Therefore, a tradeoff exists between interpretabil-
ity and performance, which is controlled through the number of trajectories. In Figure
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Extraction Proposed BN-I DBN-I DBN-G
Filtering U A PS PP A&PS A&PP
Figure 1: The log-likelihood of top n disease trajectories explaining
the disease progressions most.
Figure 6.3: The log-likelihood of the full model, i.e., complete list of disease trajectories
we obtained.
6.3, we visualize this tradeoff. Figure 6.3 shows the number of disease trajectories ob-
tained by the extraction algorithms with/without filtering criteria on the horizontal axis
and the corresponding log-likelihood on the vertical axis evaluated internally on the MC
data (left pane) and externally on the FHS data (right pane). Again, each color and
line type represents different extraction algorithms and filtering criteria.
6.3.4 External validation
Results of external validation are shown in the right pane of Figures 6.2 and 6.3. The
observations from the internal validation are largely mirrored in the external validation:
(i) higher number of trajectories typically lead to better log-likelihood; (ii) the Proposed
method without filtering consistently outperforms the competing methods; (iii) there are
filtering methods (PS and A&PP ) that achieve higher likelihood with fewer trajectories
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than the competing methods. Small inconsistencies exist in Figure 6.2. For example,
association-based filtering A outperforms the unfiltered set U for the top 5 trajectories.
This suggests that the ranking of the trajectories is slightly different between MC and
FHS, which is unsurprising given the significantly different patient populations that
these two health systems serve.
6.4 Discussion
Ongoing initiatives in health care including evidence-based medicine, precision medicine,
and learning health systems emphasize the use of all available data for decision mak-
ing. One important type of information, which is almost completely ignored in today’s
clinical practice, is disease trajectories. Trajectories are useful in medical sciences for
understanding disease progression patterns, in clinical practice for risk stratification,
and in health care delivery for focusing preventive efforts on the diseases the patient
is most likely to develop next along the trajectory. However, high performance in ex-
plaining follow-up outcomes, internal and external validity, interpretability, and correct
ordering of diseases along each trajectory are critical for these applications.
Definitions of trajectories Trajectories can be defined in many different ways. Tra-
jectories have been viewed before for example as time series of lab results[114, 115, 125].
In diabetes, trajectories of HbA1c have been shown to be predictive of outcomes decades
before the onset of those outcomes[114, 115]. Lab results trajectories are trivially visu-
alizable and interpretable, and can be integrated into risk models[125]. However, these
trajectories only look at a single aspect of the patient’s health, namely the condition
that is described by the lab result in question.
In our work, we defined trajectories more broadly, providing a more comprehensive
view of the multiple facets of complex conditions like diabetes. Our trajectories are
sequences of clinical events (phenotypes) representing the worsening of the metabolic
syndrome. Trajectories defined in this way are self-explanatory, offering a straightfor-
ward interpretation as long as the number of trajectories is not overwhelming. Since the
clinical events can describe multiple facets of health, these trajectories can simultane-
ously encompass many aspects of a disease or a syndrome. We showed that trajectories
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defined in this way and extracted through our novel algorithm can explain observed
outcomes in two independent health systems equally well and substantially better than
competing approaches.
High performance Log-likelihood assesses the ability of a set of trajectories to ex-
plain the observed outcomes (follow-up disease set). We have shown that our proposed
method achieves a higher likelihood than the competing methods, but likelihood by itself
is not intuitive making it difficult to assess how well the trajectory set predicts the out-
comes. Over the first 10 trajectories, the probability of the observing the next outcome
along the trajectory is on average 46.9% (IQR 29.4% to 63.1%) higher than assuming
that the outcomes develop independently of each other (given the set of diseases that
the patient had at baseline) and subsequent outcomes have even higher probability.
This means that the trajectories enrich the patient subpopulation that follows them
with positive outcomes, even given the baseline diseases. Since the baseline diseases
are given, this enrichment is possible because diseases develop in a number of typical
sequences and our algorithm successfully extracted these sequences.
Internal and external validity Our experimental setup through using out-of-bag
samples ensures internal validity; and we have shown that the key conclusions remained
valid through external validation.
Interpretability A set of 5,000 trajectories is not easily interpretable by a human ex-
pert. We presented two ways to reduce the number of trajectories. First, we considered
the top n trajectories. Using a single trajectory, the log-likelihood is approximately -20
and using the entire trajectory set, the log-likelihood is -4.2, giving a range of 15.8 that
can be explained by additional trajectories. We developed a ranking method that could
select a small set of trajectories that could explain outcomes almost as well as the full
set. Using n = 10 trajectories improves the likelihood from -20 (for a single trajectory)
to -8, which is 76% of the possible improvement range; and using 20 trajectories im-
proves the likelihood to -5, which is 94.9% of the possible improvement. A set of 10
or 20 trajectories are small enough to be interpretable, yet they explain outcomes with
only 5% to 24% percent loss of log-likelihood relative to the full set of 5,000 trajectories.
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The second way of reducing the trajectories was to use the proposed filtering criteria
and we discuss their effect below.
Correct ordering of diseases The true set of trajectories that patients follow are
not known. In the absence of gold standard knowledge, assessing the correctness of
the trajectory set is difficult, and we present the trajectory sets in the Appendix for
the interested readers. In lieu of a formal evaluation, we discuss two ordering errors
that the competing methods made but our method avoided: developing complications
in the absence of their risk factors; and developing risk factors after the onset of their
complications. While these are both possible, they are highly atypical.
First, we look at developing complications without their risk factors. For instance,
it is well established in the literature that hypertension (HTN) is a risk factor of chronic
renal failure (CRF)[126], yet, the competing methods captured CRF without the devel-
opment of HTN. This happened, because the causal inference-based methods identified
HL as a common cause of HTN and CRF and attributed all the risk of HTN on CRF
to HL. This could be true, but it caused the causal-based method to miss the fact that
HTN is a risk factor of and precedes CRF. The proposed method avoided such mistakes
because the association-based filtering criterion discards trajectories where associated
risk factors such as HTN for CRF are missing.
Second, risk factors and complications are in the reverse order. As an example,
obesity (OB) is known as one of the main risk factors of type 2 diabetes (T2D), and
indeed, in our data sets 70% of diabetic patients have OB. However, trajectory sets
obtained by causal inference-based methods include multiple trajectories in which T2D
precedes OB. The strict/partial precedence criteria filter out such trajectories.
Generalizability . We presented our algorithm on the use-case of diabetes due to
the availability of data for external validation and our clinical expertise with this dis-
ease. However, the proposed methods are more generally applicable to diseases where




Trajectories from the proposed algorithm explain disease progressions best among the
compared algorithms. Precedence and/or association-based filtering reduced the num-
ber of trajectories significantly while preserving their ability to explain disease progres-
sions in both cohorts and helped the proposed method order diseases along the trajectory
more correctly than competing methods. Trajectories themselves are self-explanatory
and the filtered sets are sufficiently concise to maintain interpretability by clinicians.
Chapter 7
Contributions to Science
7.1 Contribution to Health Informatics
In this thesis, we have developed a number of methodologies that directly help discover
trajectories, and many of them are also more generally applicable to other domains.
First, our main contribution is new methods to discover disease trajectories from
EHRs data. EHR data poses several key challenges to extract true trajectories due
to inaccurate timestamps and limited follow-up. In order to address these challenges,
we proposed trajectory discovery methods with two different approaches. The first
approach uses likelihood estimation to find a typical trajectory and enumerates the
atypical trajectories based on which conditions of the typical trajectory are “skipped”.
The second approach extracts a comprehensive list of trajectories from EHR data and
selects meaningful trajectories using filtering criteria based on association and prece-
dence of two succeeding diseases on trajectories. We claim that our two methods can
overcome above challenges.
Second, we proposed a new knowledge-driven data representation for clinical data
mining, including trajectory mining. A data representation for trajectory mining needs
to be high interpretable representation and must help achieve high performance on
analytics based on binary or event input data. We demonstrated that our proposed
representation is interpretable, as the variables it uses follow clinical reasoning, and it
offers the overall highest performance among competitive representations on association
analysis. High performance on association analysis is particularly important as our
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trajectory mining algorithm will largely be based on association analysis algorithms.
Third, we proposed a novel approach to estimate the onset time of disease from
intermittent observations with informative censoring. Many research questions rely on
the accurate estimation of onset times for diseases. Because of the inherent limitations
of EHR data, we cannot always directly extract this information from EHRs as they
contain the recorded time for diseases rather than the onset time. We demonstrated
the effectiveness of the proposed method through a concrete application, in which we
estimate the onset time of T2D based on the intermittently observed trajectory of HbA1c
to optimize the time when a patient needs to come back for diabetes screening.
7.2 Anticipated contributions to Medicine
Diabetes is heterogeneous, its manifestation can differ from patient to patient; patients
belonging to separate subtypes of diabetes show different progression over time. Un-
derstanding the heterogeneity needs to be a key part of providing personalized diabetes
care. However, the majority of existing studies show limited capabilities in differentiat-
ing patients. Existing studies only assess the patient’s conditions at a specific point in
time but do not fully utilize all information such as patient’s medical history. Therefore,
these studies show insufficient abilities of explicitly modeling population heterogeneity
or identifying groups that benefit for an intervention. In this thesis, we aim to extract
Type 2 Diabetes (T2D) trajectories, temporal sequences of events towards T2D. The
followings are anticipated contributions to medicine.
First, T2D trajectories allow us a precise way to quantify the risk of T2D from
subpopulations. Assessing the risk correctly is especially important for improving out-
comes. The overestimation of T2D risk can lead to unnecessary medical expenses due to
aggressive intervention including shortening follow-up periods, and the underestimation
can lead to the failures of providing proper intervention in a timely manner resulting in
the worsening of the patient’s condition.
Second, T2D trajectories allow us to assess a likelihood of upcoming events given
patient’s current conditions. T2D, its comorbidities and complications progress slowly
over time, but progression is not reversible in general. Therefore, it is important to
forecast the impending complications so that we can proactively help patients avoid or
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delay progression. Each disease has its own risk models and guidelines, yet, there is no
risk model or guideline that can cover these diseases comprehensively.
Third, T2D trajectories allow us to define the intervention group precisely. One of
the common clinical practice issues is that aggressive intervention without a compre-
hensive understanding of the patient’s health can cause adverse events[127]. On the
other hand, aggressive intervention without a comprehensive understanding of the pa-
tient’s health can lead to a waste of medical resources. We expect that our proposed
trajectories can help physicians and other health professionals select only patients who
need treatment. This can improve the outcome and minimize adverse events as well.
Finally, T2D trajectories can be integrated into clinical decision support systems
(CDSS). The CDSS can trace patient’s medical history in EHRs and can infer trajecto-
ries that are likely to follow. Therefore, we expect that the CDSS can assist physicians
and other health professionals with clinical decision tasks mentioned above efficiently
and effectively in real time.
Chapter 8
Summary and Conclusion
In this thesis, we have conducted several studies aimed to discover type 2 diabetes (T2D)
trajectories from Electronic Health Records (EHR) data.
The first study proposed a new clinical representation to make data more clini-
cally understandable and to enrich it with clinical knowledge to support personalized
healthcare. The proposed representation summarized numerous facets of a disease into
a single hierarchical variable where the hierarchy replicates the clinical reasoning steps
of determining the severity of a certain disease. We demonstrated that our proposed
representation is interpretable, as the variables it uses follow clinical reasoning, and it of-
fers the overall highest performance among competitive representations on two common
analytic tasks, regression and association analysis.
The second study aimed to develop a predictive model to estimate onset time of
slow onset diseases primarily based on their defining laboratory results. In this work, we
modeled the patients’ HbA1c trajectories through Bayesian networks (BN) to estimate
the onset time of diabetes. The BN was applied to describe dependency relationships
among variables, enabling the separation of the (unobservable) actual and observed
HbA1c level. We demonstrated that the proposed model reflects the actual changes
in HbA1c level well, and we also showed that the model has the ability to accurately
estimate the time to the onset of diabetes.
The third study aimed to focus on whether the trajectory influences the risk of T2D.
Maximum likelihood via the chain rule was used to find a typical trajectory among po-
tential trajectories. We identified a typical trajectory that most people follow, which is a
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sequence of diseases from hyperlipidemia (HLD) through hypertension (HTN), impaired
fasting glucose (IFG) to T2D. Further, we found that the sequence of comorbidities that
a patient followed was predictive of his/her T2D risk even after adjusting for the sever-
ities of the comorbidities.
In the fourth study, we proposed a new computational method for learning disease
trajectories from EHR data. The proposed method consists of three parts: first, an
algorithm for extracting trajectories from EHR data, second, three criteria for filtering
trajectories, and third, a likelihood function for assessing the risk of developing a set
of outcomes given a trajectory set. We confirmed that the proposed algorithm can
extract the most comprehensive disease trajectory set available on data, and the use
of the proposed filtering criteria selects a small subset of disease trajectories that are
highly interpretable with a minimal loss of the ability to explain disease progressions in
a cohort.
In conclusion, we demonstrated that the proposed methodologies can overcome the
limitations of EHR data for trajectory mining, and we successfully developed a method-
ology that extracts clinically meaningful disease trajectories that can explain the obser-
vation well.
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Table A.1: The baseline and its follow-up characteristics and phenotypes.
Abbreviation Description Definition
OB Obesity One or more BMI ≥ 30
HL Hyperlipidemia
Any two or more Dx, LDL ≥ 130
mg/dL, Rx
HTN Hypertension
Any two or more Dx, [SBP ≥ 140
mg/dL or DBP ≥ 90 mg/dL] Rx
IFG Impaired fasting glucose
Any two or more Dx, [A1c ≥ 5.7 % or
FG ≥ 100 mg/dL or RG ≥ 140 mg/dL],
Metformin
DM Type 2 diabetes
Any two or more Dx [A1c ≥ 6.5 or FG
≥ 125 mg/dL or RG ≥ 200 mg/dL], Rx
CRF Chronic renal failure
[One or more Dx and one or more GFR
60 ml/min/1.73 m2] or [Three or more
GFR 60 ml/min/1.73 m2]
PVD Peripheral vascular disease One or more Dx
CAD Coronary artery disease One or more Dx
MI Myocardial infarction One or more Dx
CVA Cerebrovascular accident One or more Dx






   
   
   
   
   
   
  
      
Figure A.1: Bayesian network.
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(iii) Unrolled DBN for the process duration
Figure A.2: dynamic Bayesian network.
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